An antisense oligonucleotide-based strategy to ameliorate cognitive dysfunction in the 22q11.2 Deletion Syndrome

Authors

Pratibha Thakur[1, †], Martin Lackinger[1, †], Anastasia Diamantopoulou[1,2, ‡], Sneha Rao[1], Yijing Chen[1,3], Khakima Khalizova[1], Annie Ferng[4], Curt Mazur[4], Holly Kordasiewicz[4], Robert J. Shprintzen[5], Sander Markx[6,7], Bin Xu[6,7], Joseph A. Gogos[1,2,6,8,*]

Affiliations

[1]Mortimer B. Zuckerman Mind Brain and Behavior Institute, Columbia University, New York, NY 10027, USA
[2]Department of Physiology and Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
[3]Department of Genetics and Development, Columbia University Irvine Medical Center, New York, NY 10032, USA
[4]Ionis Pharmaceuticals, Inc., Carlsbad, CA 92010, USA
[5]The Virtual Center for Velo-Cardio-Facial-Syndrome, Inc.
[6]Department of Psychiatry, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA
[7]Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY 10032, USA
[8]Department of Neuroscience, Columbia University, New York, NY 10032, USA

[‡]Present address: Institute of Neurophysiology, Goethe University, Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany

[*]Correspondence: jag90@columbia.edu (J.A.G.)
[†]These authors contributed equally to this work.

Keywords: 22q11.2 deletion, schizophrenia, miRNA dysregulation, EMC10, hiPSC, antisense oligonucleotides, precision-psychiatry based therapeutic approach

Abstract

Adults and children with the 22q11.2 Deletion Syndrome demonstrate cognitive, social and emotional impairments and high risk for schizophrenia. Work in mouse model of the 22q11.2 deletion provided compelling evidence for abnormal expression and processing of microRNAs. A major transcriptional effect of the microRNA dysregulation is up-regulation of *Emc10,* a component of the ER membrane complex, which promotes membrane insertion of a subset of polytopic and tail-anchored membrane proteins. We previously uncovered a key contribution of EMC10 in mediating the behavioral phenotypes observed in 22q11.2 deletion mouse models. Here we show that expression and processing of miRNAs is abnormal and *EMC10* expression is elevated in neurons derived from 22q11.2 deletion carriers. Reduction of *EMC10 levels* restores defects in neurite outgrowth and calcium signaling in patient neurons. Furthermore, antisense oligonucleotide administration and normalization of *Emc10* in the adult mouse brain not only alleviates cognitive deficits in social and spatial memory but sustains these improvements for over two months post injection, indicating its therapeutic potential. Broadly, our study integrates findings from both animal models and human neurons to elucidate the translational potential of modulating *EMC10* levels and downstream targets as a specific venue to ameliorate disease progression in 22q11.2 Deletion Syndrome.

Introduction

Adults and children with the 22q11.2 Deletion Syndrome (22q11.2DS) demonstrate cognitive, social and emotional impairments (*1-3*). 22q11.2 deletions are also one of the strongest genetic risk factors for schizophrenia (SCZ) (*4*). Previous work in a model of the 22q11.2 deletion, carrying a hemizygous 1.3-Mb deficiency on mouse chromosome 16 [*Df(16)A*], which is syntenic to the 1.5Mb 22q11.2 deletion [*Df(16)A*$^{+/-}$ mice] revealed a distinct behavioral and cognitive profile (*5, 6*). Molecular analysis of the *Df(16)A*$^{+/-}$ strain provided compelling evidence for abnormal processing of brain enriched microRNAs (miRNAs) (*5, 7*). The *Df(16)A*$^{+/-}$ related miRNA dysregulation is due to (i) hemizygosity of *Dgcr8*, a component of the "microprocessor" complex that is essential for miRNA production (*8*) and (ii) hemizygosity of miRNA genes residing within the deletion, including *mir185*. Reduction of miR-185 levels and to a lesser degree of miRNAs residing outside the deletion {such as miR-485 (*7*)} result in a de-repression of *Mirta22/Emc10* gene (herein after referred to as *Emc10*), whose expression is under the repressive control of *miRNAs(7)*. Indeed, comprehensive RNA profiling of *Df(16)A*$^{+/-}$ mice found that postnatal elevation in the expression of *Emc10* gene represents a key transcriptional effect of the 22q11.2 deletion (*7*). Increased brain expression of *Emc10* is recapitulated in *Df(16)A*$^{+/-}$ primary neurons(*9*) as well as in mouse models of the more common 3Mb 22q11.2 deletion (*10*). Other miRNA targets are dysregulated, but their levels of change are subtler and more variable. *Emc10* encodes for a component of the ER membrane complex (EMC), which promotes membrane insertion and maturation of a subset of polytopic and tail-anchored membrane proteins including neurotransmitter receptors, channels, and transporters (*11-18*). *Emc10* is a prenatally biased gene with high expression in embryonic life that gradually subsides after birth (*7*), a developmental pattern of expression conserved between mice, humans and nonhuman primates (*19*). *Emc10* LoF mutation that leads to reduction of *Emc10* levels rescues key cellular, cognitive and behavioral alterations in the *Df(16)A*$^{+/-}$ mice (*19*).

Here we show that 22q11.2 deletion results in abnormal processing of miRNAs in human neurons and in turn drives misexpression of *EMC10* as previously described in animal models (*5*). Human *EMC10* expression is elevated in neurons derived from 22q11.2 deletion carriers and reversal of *EMC10* expression leads to restoration of key morphological and functional alterations linked to 22q11.2 deletions, supporting normalization of *EMC10* expression as a disease-modifying intervention. Toward this end, we also show that antisense oligonucleotide (ASO)-mediated *Emc10* normalization in the adult mouse brain is effective at reversing cognitive alterations. Improvements in cognition are sustained for over two months post ASO administration. The observations that ASO-mediated Emc10 reduction in adult mouse brain rescues cognitive deficits linked to 22q11.2 deletion strongly support a key contribution of Emc10 and Emc10-dependent membrane protein trafficking in mediating the effects of 22q11.2 deletions on cognitive function and pave the way towards translating these observations into potential disease-modifying therapeutic interventions.

Results

To investigate whether miRNA dysregulation and upregulation of *EMC10* is also prominent in cortical neurons from patients carrying 22q11.2 deletions (**Fig. 1A**), we used hiPSC lines obtained from three independent 22q11.2DS/SCZ donors with a 3Mb deletion diagnosed with SCZ and matched healthy controls (**Supplementary Table 1**). The first patient/control pair is derived from dizygotic twins discordant for the 22q11.2DS and SCZ [Q6 (22q11.2) and Q5 (Ctrl)] (**Fig. S1A-D**). The second patient/control pair is derived from siblings [Q1 (22q11.2) and Q2 (Ctrl)] while the third patient/control pair is a case and age/sex matched unrelated control pair from the NIMH Repository and Genomic Resource [QR27 (22q11.2) and QR20 (Ctrl)].

We examined whether 22q11.2 deletion results in abnormal processing of miRNAs in human neurons as we have previously described in animal models (*5*). We performed parallel small RNA/miRNA sequencing on DIV8 differentiated human cortical neurons from the sibling (Q5/Q6) pair derived using an approach that combines small-molecule inhibitors to repress SMAD

and WNT signaling pathways to promote CNS fate (*20*). We confirmed the efficiency of differentiation using immunohistochemistry (IHC) and gene expression assays, which indicated the anticipated increase of TUJ1/TBR1 positive derived neurons and downregulation of embryonic stem cell marker *OCT4* (**Fig. 1B** and **Fig. S1E-G**). We identified a number of mature miRNAs dysregulated in response to the 22q11.2 deletion (**Fig. 1C**, **Fig. S2A, B, Supplementary Table S2**). As a validation of our approach, we observed the expected downregulation of miRNAs miR-185, miR-1286 and miR-1306 that reside in the 22q11.2 locus (three other predicted 22q11.2 miRNAs, miR-649, miR-3618 and miR-4761 were not detected in DIV8 neurons) (**Fig. S2A)**. Among miRNAs located outside the 22q11.2 region, we note downregulation of miRNAs such as miR-137 as well as miR-134 and several other members form the largest placental mammal-specific miRNA gene cluster miR379-410 (**Fig. S2B)** that have been previously implicated in neuronal development, differentiation and function (*5, 21-29*). We used the miRNA-target interaction network tool miRNet 2.0 (*30*) to perform target enrichment and network analysis for the dysregulated miRNAs and performed GO term enrichment analysis on this target interaction network. Affected biological processes were prominently centered on cell division and intracellular protein transport (**Fig. S3A**) whereas cellular components were associated with the nucleus and the perinuclear region (endoplasmic reticulum and Golgi apparatus) of the cytoplasm (**Fig. S3B**).

In addition to 22q11.2 deletion region miRNAs, lower abundance of miRNAs in cases is likely due to haploinsufficiency of the *DGCR8* gene and is expected to result in upregulation of target genes. To identify candidate miRNA target genes we performed an unbiased evaluation of the transcriptional responses using bulk RNA sequencing on RNA collected from DIV8 differentiated cortical neurons derived from the patient (Q6) and the corresponding healthy dizygotic twin (Q5) line (**Fig. S4A**). We observed the expected downregulation of genes within the 22q11.2 locus in patient neurons (**Supplementary Table 3**). Further, RNA and protein expression characterization confirmed the reductions in the abundance of the 22q11.2 locus residing genes *DGCR8* and *RANBP1* (**Fig. S4B, C**). Among the differentially expressed genes

(DEGs) 2094 were downregulated and 1937 were upregulated. As expected EMC10 expression was elevated in patient neurons while expression of other EMC subunits (*EMC1-4, EMC6-9*) detected in our DIV8 sequencing data did not show significant differences. GO term enrichment analysis on downregulated DEGs identified significantly altered biological processes centered on neurogenesis, neuronal development, and differentiation (**Fig. S4D**). Among the upregulated DEGs, the GO terms enriched were related to neuronal development as well as neuronal cilia assembly and structure (**Fig. S4E**).

Intersection of predicted targets of downregulated miRNAs and up-regulated DEGs identified 774 predicted targets of downregulated miRNAs (**Fig. S4F, Supplementary Table 4**) including *EMC10*. Notably, functional annotation revealed that predicted targets of downregulated miRNAs include genes that modulate neuronal development and are associated with GO terms such as endoplasmic reticulum and endomembrane system of neurons (**Fig. S4G, H**).

qRT-PCR assays confirmed a robust and significant upregulation of *EMC10* levels in RNA extracted from cortical neurons derived from hiPSCs of the Q5/Q6 pair through SMAD/WNT signaling inhibition, at three distinct stages of in vitro maturation (**Fig. 1D-F**). Additionally, this upregulation was confirmed in protein extracts from cortical neurons at day 8 of differentiation (**Fig. 1G**). To examine whether transcriptional *EMC10* upregulation is independent of the neuronal derivation method, we generated neurons via inducible expression of Neurogenin-2 (NGN2), a widely used protocol that generates a robust population of excitatory neurons (NGN2-iNs) within 3 weeks (*31-34*). MAP2 staining was used to demonstrate the successful neuronal differentiation of the hiPSC lines (**Fig. 1H**). qRT-PCR assay of *EMC10* mRNA expression level in NGN2-iNs at DIV21 confirmed transcriptional *EMC10* upregulation in three independent pairs of patient and sex-/age matched healthy control lines (**Fig. 1I-K**). Taken together our results highlight a reproducible and robust upregulation of *EMC10* in neurons derived from patients with 22q11.2 deletions, which is independent of the derivation method. It is noteworthy that in addition to monolayer cultures, *EMC10* shows significant upregulation along the excitatory neuron lineage

(radial glia, intermediate progenitors and excitatory neurons) but not in astrocytes, choroid or interneuron lineage cells, in patient forebrain organoids generated by the same hiPSCs lines used in the present study (*35*).

We have previously shown that upregulation of the murine orthologue of *Emc10* is primarily due to downregulation of miR-185 and to a lesser degree of miR-485 (*7*). Both conserved and non-conserved binding sites at the 3'UTR of human *EMC10* are predicted in silico for both miRNAs (**Fig. S5A**). Consistently, the observed upregulation in the levels of *EMC10* gene is accompanied by a robust reciprocal decrease in the levels of the miRNA precursor of miR-185 at DIV8 as indicated both by our miRNA sequencing analysis (**Fig. 2A, Supplementary Table 2**) and follow up qRT-PCR assays (**Fig. 2A**). miRNA precursor of miR-485 showed a more modest non-significant reduction in its abundance (**Fig. 2B**). Notably, overexpression of miR-185 and miR-485 using miRNA mimics in human cortical neurons at DIV10 resulted in reduction of *EMC10* expression levels in both the healthy control (Q5, **Fig. 2C**) and patient line (Q6, **Fig. 2D**). Furthermore, inhibition of endogenous miR-185 and miR-485 in the control line by using specific miRNA inhibitors increased *EMC10* expression level (**Fig. 2E**) confirming the predicted conserved functionality of miR-185 and miR-485 miRNA binding sites in *EMC10*. It is worth noting that in addition to miR-185, non-conserved binding sites at the 3'UTR of human *EMC10* are predicted *in silico* for two additional downregulated miRNAs residing within the 22q11.2 locus, miR-1286 and miR-1306 (**Supplementary Table 5**). The functionality of these miRNA binding sites in *EMC10* and whether they contribute to the observed elevation of its expression in human neurons remains to be determined. Taken together our results confirm that miRNA dysregulation emerges in human neurons as a result of the 22q11.2 deletion and in turn drives misexpression of genes primarily involved in intracellular membrane and protein trafficking-related processes required for neuronal development and maturation. Among them, *EMC10* represents a major downstream effector of the 22q11.2-linked miRNA dysregulation.

To investigate the relevance of *EMC10* de-repression in the development and function of patient neurons, we generated derivatives of the Q6 patient hiPSC line carrying either heterozygous (Q6/EMC10^{HET}) or homozygous (Q6/EMC10^{HOM}) *EMC10* LoF mutations using standard CRISPR/Cas9 editing approaches (**Fig. S6A**). Mutations were confirmed by sequencing (**Fig. S6A**, lower panel) and karyotyping confirmed normal chromosome complement (**Fig. S6B**). We confirmed reduced expression levels of 22q11.2 gene *RANBP1* by western blot in both derivative hiPSC lines (**Fig. S6C**) whereas stem-cell marker *NANOG* and *OCT4* were equally expressed in all lines assayed by qRT-PCR (**Fig. S6D, E**). EMC10 mRNA and protein levels were reduced by ~50% in the Q6/EMC10^{HET} hiPSC line and abolished in the Q6/EMC10^{HOM} line (**Fig. S6F, G**). It is noteworthy that we did not observe an upregulation of *EMC10* mRNA levels in the Q6 hiPSC lines (**Fig. S6F**), a finding likely attributed to the general low expression level of miR-185 and miR-485 in hiPSCs (*36*). Indeed both miRNAs are developmentally regulated and show increased expression levels during neuronal development (https://ethz-ins.org/igNeuronsTimeCourse/) (*37*). Additional characterization of hiPSC-derived NGN2-iNs (**Fig. 3A**), conclusively demonstrated a reduction (Q6/EMC10^{HET}) or elimination (Q6/EMC10^{HOM}) of *EMC10* mRNA (**Fig. 3B**). Expression assays of a panel of cell type-specific markers did not reveal significant differences between NGN2-iNs from the Q6 patient line and both derivative lines, indicating that gene editing has no adverse effect on neuronal differentiation (**Fig. S6H)**.

Df(16)A$^{+/-}$ mice show impaired formation of dendrites in deep layer cortical neurons, which are faithfully recapitulated in primary neuronal cultures and are partially reversed by reduction of *Emc10* levels (*7*). We asked whether impaired dendritic formation is also observed in human neuronal cultures from patients with 22q11.2 deletions and whether reduction of *EMC10* levels could prevent such morphological alterations during neuronal maturation. We employed monolayer neuronal cultures of NGN2-iNs. Neuronal cells were fixed at DIV21 of differentiation, immuno-stained, traced and key indices of dendritic architecture were quantified (see Materials

and Methods). Our analysis confirmed a reduced dendritic complexity in mutant neurons as reflected in total neuronal length, the number of branch points and the total number of dendrites per cell (**Fig. 3C-F**). The number of primary dendrites per cell were unchanged (**Fig. 3G**) in accordance with previous findings from the murine 22q11.2 deletion model where only subtle changes were detected in the number of primary neurons (*7*). Importantly, we found that reduction or elimination of *EMC10 expression* restored to WT levels neuronal length and branchpoints.

Our previous evaluation of Ca^{2+} homeostasis perturbations caused by 22q11.2 deletions using Ca^{2+} imaging on primary neurons from *Df(16)A*$^{+/-}$ mice revealed a significantly lower amplitude of Ca^{2+} elevation following KCl evoked depolarization (*9*). This impairment was replicated in human cortical neurons from patients with 22q11.2 deletions (*38*) and shown to be partially restored by exogenous expression of *DGCR8*, indicating a potential role of miRNA dysregulation. Using the green-fluorescent calcium indicator Fluo-4 and time-lapse microscopy we confirmed a decrease in the amplitude of Ca^{2+} rise following KCl evoked depolarization, in patient (Q6) derived NGN2-iNs at DIV37/38 compared to the healthy twin (Q5) (**Fig. S7A, B**). We asked whether reduction of EMC10 levels could reverse such alterations. Notably, the observed defect in Ca^{2+} signaling were reversed in both Q6/EMC10^{HET} and Q6/EMC10^{HOM} NGN2-iNs as demonstrated by the increased amplitude of Ca^{2+} rise following depolarization (**Fig. 3H, I**). The observation that reduction of *EMC10* levels fully restores the Ca^{2+} signaling deficits observed in *patient neurons* suggests that miRNA-dependent elevation in *EMC10* levels may interfere with one or more sources of intracellular Ca^{2+} and a wide range of calcium-dependent processes.

Differentially expressed genes are often organized into functional groups or pathways based on their known biological roles. We used transcriptional profiling as an indirect measure of cellular pathways affected by the reduction of EMC10 levels by identifying genes differentially expressed between the parental Q6/Q5 lines whose expression differences are abolished or nearly abolished in either Q6/EMC10^{HET} or Q6/EMC10^{HOM} NGN2-iNs (**Fig. 3J, K**). We identified 237 (111 downregulated and 126 upregulated) and 382 (193 downregulated and 189 upregulated)

such DEGs, respectively (**Supplementary Table 6**). In both cases, functional annotation analysis indicated highest enrichment scores for terms related to nervous system development as well as an enrichment in GO terms relevant to neuronal generation and differentiation. Intersection of "rescued" genes in Q6/EMC10^{HET} and Q6/EMC10^{HOM} NGN2-iNs identified 103 shared DEGs (**Supplementary Table 7**). Protein-protein interaction (PPI) analysis highlighted a functional cluster including 30 of these genes, such as the SCZ-associated genes *PCDHA2 (39), RBFOX1 (40)* and *RGS4 (41, 42)* (**Fig. S8A**), involved in nervous system development (**Fig. S8B**). It should be noted that the beneficial effect of elimination of EMC10 expression is consistent with previous findings indicating that lack of EMC10 does not compromise EMC assembly (*43*) and implying an auxiliary or modulatory role of EMC10 in the EMC function.

Taken together, our analysis of neurons from 22q11.2 deletion carriers indicate that elevation of *EMC10* expression disrupts their development and maturation in a way similar to observations in murine neurons, and support normalization of *EMC10* expression as a disease-modifying intervention. While our previous work has shown that constitutive genetic reduction of *Emc10* levels rescues key cognitive and behavioral alterations in the *Df(16)A*$^{+/-}$ mice, translating these observations into therapeutic interventions requires demonstration that it is the sustained elevation of *EMC10* throughout the adult life that interferes with the underlying neural processes rather than an irreversible impact on brain maturation during early development. Toward this end, we first investigated whether restoration of *Emc10* levels in the brain of adult (2–4-month-old) *Df(16)A*$^{+/-}$ mice is effective at reversing cognitive alterations (*5, 19*). Specifically, we examined the effects of *Emc10* reduction in adult brain on SM, a cognitive domain robustly and reproducibly affected in adult *Df(16)A*$^{+/-}$ mice (*6, 19, 44*). Notably, SM deficits are also present in juvenile *Df(16)A*$^{+/-}$ mice as early as postnatal day 22 (**Fig. S9A, B**), underscoring the severity of this phenotype, which emerges during early adulthood. Deficits in social cognition are present in individuals with 22q11.2 deletions and use of rodent tasks that evaluate SM can serve as a useful proxy of the human condition. Impaired SM in *Df(16)A*$^{+/-}$ mice is fully restored by constitutive

genetic reduction of *Emc10* levels (*19*). To manipulate the expression of the *Emc10* gene in adult *Df(16)A*$^{+/-}$ mice we used a *Emc10* conditional 'knockout-first' design by conducting a Flp- and Cre- dependent genetic switch strategy (**Fig. S10A**). Parental *Emc10*$^{+/- tm1a}$ mice were crossed to a germline Flp mouse line that activates global Flp function and leads to the deletion of the frt-flanked sequence(s) in the offspring. The *Emc10*^{tm1c} offspring from this cross carry a *loxP* flanked WT *Emc10* allele and are essentially WT. To achieve temporal control of *Emc10* expression we used an inducible UBC-Cre/ERT2 mouse line that activates global Cre function upon tamoxifen (TAM) treatment. This approach enables postnatal normalization of *Emc10* expression at its endogenous locus preserving *Emc10* expression within its physiological levels. We used UBC-Cre/ERT2 mice in crosses to generate compound *Emc10*$^{tm1c+/-}$; UBC-cre/ERT2; *Df(16)A*$^{+/-}$ mice. These mice have two WT *Emc10* copies upregulated, as expected in the *Df(16)A* background, until TAM-induced Cre expression deletes the tagged *Emc10* allele. We used oral gavage to deliver TAM and implement Cre-mediated *Emc10* deletion during adulthood (postnatal day 56-70). Corn oil treatment served as a control. Behavioral analysis was performed on the following four groups: *Emc10*$^{tm1c+/-}$; UBC-cre/ERT2; *Df(16)A*$^{+/+}$ mice treated with TAM (WT + TAM), *Emc10*$^{tm1c+/-}$; UBC-cre/ERT2; *Df(16)A*$^{+/-}$ mice treated with TAM (*Df(16)A*$^{+/-}$ + TAM), *Emc10*$^{tm1c+/-}$; UBC-cre/ERT2; *Df(16)A*$^{+/+}$ mice treated with corn oil vehicle (WT + oil), and *Emc10*$^{tm1c+/-}$; UBC-cre/ERT2; *Df(16)A*$^{+/-}$ mice treated with corn oil vehicle (*Df(16)A*$^{+/-}$ + oil). Investigation of the efficiency of Cre-mediated deletion in brain lysate preparations from prefrontal cortex (PFC) (**Fig. S10B, C**), hippocampus (HPC) (**Fig. S10D, E**) and cerebellum (CB) (**Fig. S10F**) confirmed that upon TAM treatment, *Emc10* mRNA and protein levels were restored to near WT levels in the adult brain of *Df(16)A*$^{+/-}$ mice. As expected, *Df(16)A*$^{+/-}$ + oil mice showed impaired SM performance compared to WT + oil control littermates, which was fully rescued upon TAM treatment. Specifically, upon reintroduction of a familiar juvenile mouse *Df(16)A*$^{+/-}$ + TAM mice showed a strong reduction in social interaction, indicative of intact SM, comparable to TAM-treated WT littermates and significantly different from *Df(16)A*$^{+/-}$ mice treated with corn oil (**Fig.**

S10G). The intact SM of the *Df(16)A*$^{+/-}$ + TAM mice was further evident in analysis of difference score (**Fig. S10H**) compared to the corn oil-treated *Df(16)A*$^{+/-}$ mice. By contrast, *Df(16)A*$^{+/-}$ mice hyperactivity in the open field was not affected upon TAM treatment consistent with our previous results from constitutive genetic reduction of *Emc10* levels (**Fig. S10I**). Overall, our findings indicate that restoration of *Emc10* levels in adult *Df(16)A*$^{+/-}$ mice has substantial effects on ameliorating cognitive deficits, indicating a broad window of therapeutic opportunity and highlighting Emc10 as a promising target for postnatal therapeutic interventions.

We explored the translation potential of this finding by employing transient injection of single stranded ASOs targeting the mouse gene as dictated by their demonstrated efficacy as a therapeutic modality in preclinical models (*45-50*) and clinical studies of neurodevelopmental disorders (NDDs) or neurodegenerative disorders (*51-53*). Over 300 chimeric 2′-O-methoxyethyl/DNA gapmer ASOs were generated and screened for *Emc10* mRNA reduction in 4T1 cells via electroporation (**Fig. S11A**). Lead ASOs were then confirmed in a dose-response assay (**Fig. S11B**), including the lead ASO (1081815, herein referred to as Emc10^{ASO1}), which targets intron 2 of mouse *Emc10* (**Fig. 4A**). Emc10^{ASO1} was selected for subsequent studies, as it was effective in lowering *Emc10* expression both in vitro and in vivo. Specifically, following transient intracerebral ventricular (ICV) injection in the posterior ventricle of 8 weeks old WT mice, Emc10^{ASO1} effectively suppressed the levels of *Emc10* mRNA (**Fig. S11C**) and protein (**Fig. S11D**) in both left and right HPC compared to WT mice treated with a control ASO (Ctrl^{ASO1}) without complementarity in the mouse. Analysis of *Gfap* and *Aif1* expression did not reveal any changes (**Fig. S11E, F**) suggesting lack of astroglial and microglial activation upon Emc10^{ASO1} injection. Emc10^{ASO1} injected mice showed normal gait and no signs of behavioral toxicity. IHC analysis using an antibody that selectively recognizes the phosphorothioate backbone verified a robust diffusion primarily in HPC and to a lesser degree in surrounding brain areas. Colocalization with the neuronal marker NeuN and glial fibrillary acidic protein (GFAP) confirmed accumulation in hippocampal neurons as well as GFAP-expressing astrocytes (**Fig. 4B**). Analysis of *Df(16)A*$^{+/-}$

mice treated by intraventricular injection at 8 weeks of age showed that Emc10^{ASO1} effectively lowered hippocampal *Emc10* mRNA to nearly WT levels 3 weeks post-injection resulting in normalization of *Emc10* expression (**Fig. 4C**, left panel). By contrast, consistent with the pattern of ASO distribution, we did not observe a significant reduction of *Emc10* expression levels in the prefrontal cortex (PFC) of *Df(16)* $^{+/-}$ mice treated with Emc10^{ASO1} (**Fig. 4C**, right panel). In addition to targeted assays, we performed bulk RNA-sequencing analysis of Ctrl^{ASO1} and Emc10^{ASO1}-treated *Df(16)A*$^{+/-}$ mice and WT littermates to evaluate the effect of Emc10^{ASO1} treatment on the hippocampal transcriptome profile. In the Ctrl^{ASO1} treated group (**Fig. 4D**, left panel), we observe the tripartite differential gene expression signature characteristic of *Df(16)A*$^{+/-}$ mice: upregulation of *Emc10* and non-coding RNAs (pri-forms of miRNAs and long non-coding RNAs (**Fig. 4D**, left panel and inset, Log2Fold Change = 0.5) as well as the expected downregulation of genes included within the *Df(16)A* deficiency. In the Emc10^{ASO1} treated group (**Fig. 4D**, right panel and inset), *Emc10* is no longer upregulated in *Df(16)A*$^{+/-}$ mice while non-coding RNAs remain upregulated, and genes included in the deficiency are robustly downregulated. Apart from *Emc10*, seven other genes (*Mir9-3hg*, *Plxnd1*, *Cd68*, *Mir22hg*, *Gm28439*, *Adgre1*, and *Tnn*) are significantly upregulated in *Df(16)A*$^{+/-}$ mice in the Ctrl^{ASO1} but not in the Emc10^{ASO1}-treated group (**Supplementary Table S8**). We used the Bowtie mapping tool (*54*) to align short sequencing reads on both genomic and transcript sequence to assess whether these expression changes represent potential off-target effects of the Emc10^{ASO1} in the mouse transcriptome. Emc10^{ASO1} exclusively aligned with full complementarity to an intronic region in the *Emc10* gene (**Fig. 4A**) providing additional support for high target specificity. The observed changes might represent downstream effects of *Emc10* level reduction or reflect expression variability due to low expression levels of the upregulated genes.

Eight-week-old *Df(16)A*$^{+/-}$ mice and WT littermates were treated by ICV injection of Emc10^{ASO1} and Ctrl^{ASO1} and tested 3 weeks later in SM assays. *Df(16)A*$^{+/-}$ mice treated with Ctrl^{ASO1} showed the expected deficits in SM as reflected in the sustained high interaction time with

the reintroduced familiar juvenile mouse. By contrast, *Df(16)A*$^{+/-}$ mice injected with Emc10^{ASO1} had significantly improved performance to levels indistinguishable from Emc10^{ASO1}-treated WT littermates consistent with improvement of function arising from adult restoration of *Emc10* levels (**Fig. 4E, F**). Rescue was observed in both sexes and no significant differences were seen in treatment across sexes. In control experiments, we did not observe any effects of genotype or treatment upon reintroduction of a novel juvenile mouse in trial 2 (**Fig. S12A, B**), strongly indicating that SM deficits are not driven by a simple task fatigue.

To evaluate the consistency and reproducibility of the ASO-mediated SM rescue, we generated additional ASOs and screened them for *Emc10* mRNA reduction *in vivo* (**Fig. S13A-C)**. One of these ASOs (1466182, herein referred to as Emc10^{ASO2}), which targets intron 1 of mouse *Emc10* (**Fig. 5A**) was selected as the lead ASO for the replication analysis based on its efficacy in reducing *Emc10* levels, distribution pattern, as well as the lack of any signs of astroglial/microglial activation or behavioral toxicity (see Materials and Methods). IHC analysis showed robust distribution in both HPC (**Fig. S14A**, top panel) and PFC (**Fig. S14A**, middle panel) as well as diffusion into both neuronal and non-neuronal cells (**Fig. S14A**, bottom panel). qRT-PCR analysis of *Df(16)A*$^{+/-}$ mice treated by intraventricular injection at 8 weeks of age showed that Emc10^{ASO2} effectively lowered *Emc10* mRNA to nearly WT levels 3 weeks post-injection resulting in normalization of *Emc10* expression in the HPC (**Fig. 5B**), PFC (**Fig. 5C**) and somatosensory cortex (**Fig. 5D**). To study the effects of Emc10^{ASO2}-mediated *Emc10* reduction on SM performance, 8-week-old *Df(16)A*$^{+/-}$ male mice and WT littermates were treated by ICV injection of Emc10^{ASO2} and Ctrl^{ASO2} and tested 3 weeks later. *Df(16)A*$^{+/-}$ mice injected with Emc10^{ASO2} had significantly improved SM performance to levels indistinguishable from Emc10^{ASO2}-treated WT littermates (**Fig. 5E, F**).

In addition to SM deficits, *Df(16)A*$^{+/-}$ mice show a spectrum of cognitive impairments in episodic and spatial memory as reflected, for example, in impaired performance in an Y-maze-based delayed alternations task that probes short-term spatial memory (*55*) and contextual fear

conditioning a form of associative learning test used for studying episodic learning and spatial memory (5). We proceeded to investigate the impact of ASO-mediated Emc10 reduction in the adult brain on both of these cognitive tasks. First, we confirmed that adult male *Df(16)A*$^{+/-}$ mice exhibit impaired short-term spatial memory during novelty exploration in a two-trial delayed alternation Y-maze task (**Fig. 5G**) as previously described for another mouse model of the 22q11.2 deletion (60). The total number of arm entries remained unchanged, indicating no alternations in locomotor activity (**Fig. S14B**). To determine whether reducing Emc10 expression in the brain via ASO treatment could rescue short-term spatial memory deficits, we tested a new cohort of *Df(16)A*$^{+/-}$ mice and WT littermates 3-weeks following ASO administration (**Fig. 5H**). ASO-treated *Df(16)A*$^{+/-}$ mice exhibited a significant improvement in delayed alternations compared to *Df(16)A*$^{+/-}$ mice treated with control ASO (**Fig. 5H**). Furthermore, no significant differences in total number of arm entries were observed between the groups (**Fig. S14C**). We confirmed the reduction of *Emc10* levels in the ASO-treated animals through qRT-PCR assays of the HPC, PFC and SSC brain regions (**Fig. S14D-F**). In the contextual fear conditioning task, while ASO treatment was not sufficient to fully rescue the learning deficit in *Df(16)A*$^{+/-}$ mice to WT levels (**Fig. 5I**, right panel), there was a modest improvement in fear memory of ASO-treated *Df(16)A*$^{+/-}$ mice, since these mice did not differ significantly from the ASO-treated WT littermates. Interestingly, we have previously shown that genetic reduction of *Emc10* levels in *Df(16)A*$^{+/-}$ mice resulted in only partial restoration of deficits in contextual fear memory (*19*). Thus our finding faithfully recapitulates results from our previous constitutive genetic rescue assays (*19*) and likely indicates a more limited role of *Emc10* upregulation in the 22q11.2-linked fear memory deficits rather than requirement for additional treatment time or for earlier onset of *Emc10* normalization.

The application of ASOs as a novel therapeutic strategy has seen a significant rise in recent years, in part due to their versatility in durably modifying RNA transcripts. Therefore, we investigated the longevity of ASO-mediated repression of *Emc10* as an indicator of future therapeutic relevance for the treatment of 22q11.2DS. To this end, we conducted the SM and Y-

maze assays on a new cohort of *Df(16)A*$^{+/-}$ mice at 3-4 weeks and 8-9 weeks post injection with Emc10^{ASO2} (**Fig. 6A**). We observed behavioral rescue in Emc10^{ASO2}-treated *Df(16)A*$^{+/-}$ mice in the SM assay at three weeks (**Fig. 6B**, left panel) and in the Y-maze assay at four weeks post ASO-administration (**Fig. 6C**, left panel) in accordance to our previous findings (**Fig. 5F, H**). Remarkably, we replicated these results at 8-9 weeks post injection, demonstrating sustained behavioral rescue of SM **(Fig. 6B**, right panel) and spatial memory deficits (**Fig. 6C**, right panel). Importantly, locomotor activity remained unchanged in the Y-maze assays at both, four weeks (**Fig. S14G**) and nine weeks (**Fig. S14H**) post injection. Finally, we confirmed the downregulation of *Emc10* in ASO-treated animals via qRT-PCR assays of the HPC, PFC, and SSC brain regions at ten weeks post-treatment (**Fig. 6D-F**). These results suggest that normalizing *Emc10* expression in the brain can ameliorate social and spatial memory deficits in adult *Df(16)A*$^{+/-}$ mice in a time period of at least two months.

Discussion

Despite an understanding of the molecular mechanisms of 22q11.2DS, especially ones related to abnormal expression and processing of miRNAs (*5, 7, 19, 38, 56*), we still do not have a promising therapeutic avenue for the cognitive and neuropsychiatric symptoms associated with the 22q11.2 deletion. By leveraging our recent understanding of the molecular, cellular and behavioral consequences of 22q11.2-linked miRNA dysregulation, the present study represents an advancement towards developing a potential therapeutic strategy in two ways:

First, we show that 22q11.2 deletion results in abnormal processing of miRNAs in human neurons and in turn drives upregulation of *EMC10* levels as previously described in mouse models (*5*). Effective reduction to near WT levels or even complete depletion of *EMC10* leads to restoration of key alterations in morphological and functional neuronal maturation emerging due to 22q11.2 deletions. The miRNA regulatory mechanism underlying *EMC10* upregulation and the restoration of cellular deficits are very similar to the ones we previously described in *Df(16)A*$^{+/-}$ mice, highlighting the robustness of this molecular alteration as well as the translational value of

using animal models to probe the link between *Emc10* upregulation and 22q11.2-linked behavioral dysfunction.

Second, we show that normalization of *Emc10* levels in adult *Df(16)A*$^{+/-}$ mouse brain, by ASO-mediated targeted knockdown, is effective in rescuing SM deficits (which emerge during postnatal development and are present as early as postnatal day 22) as well as short-term spatial memory deficits. These findings strongly suggest that at least for a subset of 22q11.2-associated cognitive deficits it is the sustained miRNA dysregulation and elevation of *Emc10* throughout the adult life that interferes with the underlying neural processes rather than an irreversible impact on brain maturation during early development and demonstrate the therapeutic potential for treating a wide range of cognitive symptoms associated with 22q11.2DS.

In vivo delivery of ASOs offers a potential venue for emerging treatments of genetically driven and postnatally reversible symptoms of neurodevelopmental disorders (NDDs) focusing in reduction of culprit gene expression via sequence-specific knockdown of mRNA transcripts (*57*). A common challenge in efforts to employ gene-knockdown therapies for dosage-sensitive genes such as *EMC10* is restricting target gene expression within optimal levels to avoid potential toxicity due to target hyper-knockdown or complete elimination (*58-61*). A large number of relatively rare LoF variants or potentially damaging missense variants have been identified in the human *EMC10* gene among likely healthy individuals in gnomAD (*60, 62*) which is depleted of individuals known to be affected by severe NDDs. Taken together with our previous analysis of heterozygous *Emc10* knockout mice (*19*), these observations strongly indicate that 50% reductions in *Emc10* levels are well tolerated at the level of the organism. The highest dose for both Emc10-specific ASOs used in mutant *Df(16)A*$^{+/-}$ mice was limited to ~300 µg and reduced *Emc10* mRNA to either normal or below normal (30-50% of WT) expression while attaining full behavioral rescue. While higher dose may be required to ameliorate other behavioral deficits (*58, 60*), it should be noted that an acute injection of 700µg Emc10^{ASO} in WT mice that resulted in ~50% reduction of Emc10 levels (**Fig. S13**) did not cause secondary cellular and behavioral toxicity. Thus, available evidence indicates

that therapeutically effective ASO-mediated normalization of *EMC10* levels can be up- or down-titrated within an unequivocally safe range. Future experiments will determine whether ASO-mediated normalization of adult *Emc10* levels restores additional 22q11.2 behavioral and cognitive alterations and whether earlier onset of postnatal ASO treatment can be employed to prevent the onset of behavioral deficits or to mitigate specific behavioral deficits that do not respond to adult interventions.

In addition to reduction of *Emc10* expression our findings have implications for therapeutic interventions aiming to manipulate its downstream targets. In that respect, it is attractive to speculate that different *EMC10* upregulation-linked phenotypes and their developmental requirements may be driven by dysregulation of distinct, individually or in combinations, downstream EMC targets. Such targets are typically multi-transmembrane domain (TMD) proteins (*17, 18, 63*) that contain low-hydrophobicity TMDs which are hard to insert into ER membrane and thus require the aid of EMC as a membrane insertase (*11, 12, 17*). Identification of neurotransmitter receptors, channels, and transporters whose biogenesis, trafficking and membrane insertion are affected by EMC10 upregulation could help establish a link between such targets and 22q11.2-related behavioral dysfunction and guide efforts to develop treatments for specific 22q11.2 deletion symptoms.

Overall, by pointing to manipulations of *EMC10* expression and activity as well as of downstream targets as an attractive alternative or augmentation of currently available treatments and highlighting a broad temporal window of therapeutic and preventive opportunity for the 22q11.2 deletion-associated cognitive and behavioral symptoms, our results pave the way for developing mechanism-based therapeutic strategies, leveraging insights from both human and animal models to enhance clinical outcomes in precision medicine for neuropsychiatric disorders.

Materials and Methods

Mice: We used *Emc10* conditional knockout (see below) and *Df(16)A*$^{+/-}$ mice (*5*) in C57BL/6J background. *Df(16)A*$^{+/-}$ male mice were crossed to C57BL/6J female mice to obtain either *Df(16)A*$^{+/-}$ or WT littermates. For further details, see Supplemental Materials and Methods.

Generation of *Emc10* conditional knockout compound mouse lines: To manipulate the expression of the *Emc10* gene in *Df(16)A*$^{+/–}$ mice we used a *Emc10* conditional 'knockout-first' mouse design by conducting Cre- and Flip- dependent genetic switch strategies as described earlier (*64*). This approach enables postnatal manipulation of *Emc10* expression at its endogenous locus keeping Emc10 expression within its physiological levels. *Emc10*$^{tm1a+/}$ mice (2310044h10rik-Tm1a, MRC Harwell Institute, Oxfordshire, UK) were crossed to a germline Flp mouse line (B6.129S4-Gt(ROSA)26Sortm1(FLP1)Dym/RainJ_JAX:009086) that activates global *Flp* function and leads to the deletion of the frt-flanked sequence(s) in the offspring. The *Emc10*^{tm1c} offspring from these cross carries a *loxP* flanked WT *Emc10* allele. We used UBC-Cre/ERT2 mice (B6.Cg-Ndor1 Tg(UBC-cre/ERT2)1Ejb /2J_JAX:008085) in crosses to generate compound *Emc10*$^{tm1c+/-}$; UBC-cre/ERT2; *Df(16)A*$^{+/–}$ mice.

Cell line differentiation: The cell line donors used in this study are listed in **Supplementary Table S1**. Human iPSC lines were maintained in mTeSR Plus medium on Matrigel coated tissue culture plate and neuronal induction of hiPSC lines into cortical neurons were conducted by using either a combination of small molecule inhibitors or NGN2 overexpression approaches. For further details, see Supplemental Material and Methods.

Genome editing of Q6(22q11.2) hiPCS line. We generated derivatives of the Q6 (22q11.2) hiPSC line carrying either heterozygous (Q6/EMC10^{HET}) or homozygous (Q6/EMC10^{HOM}) *EMC10* LoF mutations using standard CRISPR/Cas9 genome editing approaches. For further details, see Supplemental Materials and Methods.

ASOs: Mouse *Emc10*-targeting ASOs used in these studies were 20 bases in length, chimeric 2' -O- (2-methoxyethyl) (MOE)/DNA) oligonucleotides with phosphodiester and phosphorothioate

linkages. The central gap of 10 deoxynucleotides is flanked on its 5' and 3' sides by five MOE modified nucleotides. Oligonucleotides were synthesized at Ionis Pharmaceuticals (Carlsbad, CA, USA) as described previously (*65, 66*). ASOs were solubilized in 0.9% sterile saline or PBS.

Stereotactic Intracerebroventricular (ICV) Injections of ASOs: ASOs were delivered to 8 weeks old mice via ICV injections using a Hamilton syringe (Hamilton Company, Reno, NV, USA) connected to a motorized Stoelting Quintessential Stereotaxic Injector QSI/53311 (Stoelting Co., Wood Dale, IL, USA). For further details, see Supplemental Materials and Methods.

Analysis of dendritic complexity: iNs were prepared on coverslips, fixed at DIV21 and immunostained for TBR1 and MAP2 to identify dendritic branches. For further details, see Supplemental Materials and Methods.

Calcium imaging: Calcium imaging was performed as previously described (*67*) with a few modifications. For further details, see Supplemental Materials and Methods.

Bulk RNAseq and bioinformatic analysis of mouse hippocampal samples: Total RNA was isolated from 4 WT Ctrl^{ASO1}, 4 WT Emc10^{ASO1}, 5 Df16 Ctrl^{ASO1} and 4 Df16 Emc10^{ASO1} treated male hippocampi. Stranded polyA+ enriched RNA sequencing libraries were prepared at the Columbia Genome Center (Columbia University, New York, USA) to generate 40 million paired-end reads on Illumina Novaseq 6000 instrument using STRYPOLYA library prep kit. For further details, see Supplemental Material and Methods.

Bulk RNAseq and small RNA/miRNAseq of hiPSC-derived cortical neurons: Total RNA was extracted from hiPSC-derived cortical neurons using the miRVana miRNA isolation kit (#AM1560, Ambion, Thermo Fisher Scientific, Waltham, MA, USA) before bulk RNAseq (paired-ended sequencing; Ilumina NovaSeq 6000) or miRNAseq (single-end sequencing; Illumina Hiseq 2500) were performed. For further details, see Supplemental Material and Methods.

Behavioral assays: Mice were 11-17 weeks old at the time of behavioral testing except of the social memory assay in juveniles which was performed in 3 week old animals. Behavior was assayed 3-9 weeks following surgical delivery of ASOs or 1 week following TAM/corn oil

treatment. The following behavioral assays were performed in this study: Open field assay, social memory assay, contextual fear conditioning and Y-maze delayed alternation task. For further details, see Supplemental Material and Methods. The experimenter was blind to mouse genotype and treatments while performing behavioral assays and data analysis. Animals were given at least one-week intervals between behavioral tests.

Statistical Analysis: Data were analyzed using GraphPad Prism (Graphpad Software, Inc., San Diego, CA, USA). Data were evaluated as indicated, using either unpaired two-tailed t-test, Kolmogorov–Smirnov test, one-way, two-way or three-way analysis of variance (ANOVA) tests followed by post hoc Tukey's multiple comparison test for comparisons across all groups. Data are presented as mean ±SEM. P values for each comparison are described in the figure legends.

Acknowledgments

We thank Dr. Huynh-Hao Bui and Andrew Watt for design and identification of ASOs, Mark Andrade and the Ionis synthesis group for ASO synthesis, and Dr. Mark Graham for ASO study design and feedback. We thank Naoko Haremaki for genotyping, maintaining the mouse colony and for assisting in the SM and Y-maze assays. We thank Panagiota Apostolou for her help with the calcium imaging setup. We thank Yan Sun and Vivian Zhu for the hiPSC line validation and maintenance. We thank Barbara Corneo and the Columbia Stem Cell Core Facility for the Q1, Q2, Q5 and Q6 hiPSC lines generation. Bio-samples of Q20 and Q27 hiPSCs were obtained from NIMH Repository & Genomics Resource. We would like to thank Zuckerman Institute's Cellular Imaging platform for instrument use and technical advice. We thank the Columbia Genome Center for genome sequencing and analysis support. We thank Linda Brzustowicz and Bill Manley from the Rutgers University and the staff members at RUCDR. Data and biomaterials generated in Study 125/Site 393 were funded by a NIMH grant to Dr. Herb Lachman (MH087840: Analysis of Glutamatergic Neurons Derived from Patient-Specific iPS Cells). The co-investigators on this grant included Dr. Deyou Zheng and Dr. Reed Carroll from the Albert Einstein College of

Medicine. Patients and controls were recruited at the Albert Einstein College of Medicine and at the Child Psychiatry Branch, NIMH, directed by Dr. Judith L. Rapoport. We thank all participating subjects and their families for their contributions. The overview Figure 6A was created with BioRender.com (agreement number:CM271GHNWZ).

Author contributions:

PT contributed to the design of the *in vivo* ASO screening and performed the ASO injections/surgeries as well as mouse related RNA and protein expression, immunohistochemistry and behavioral analysis. ML contributed to the design, characterization, expression and phenotypic analysis of human iPSC lines, the *Emc10* conditional knockout mouse-related RNA/protein expression assays and behavioral analysis, the behavioral analysis of the juvenile *Df(16)A*$^{+/-}$ mouse line, the Y-maze behavioral assays and the related behavioral assays of the long-term ASO-injected animals. Further, ML conducted the implementation and analysis of mouse fear conditioning assays and contributed to the ASO-related mouse RNA/protein expression assays. AD contributed to the design and implementation of the *in vivo* ASO screening and behavioral data acquisition. SR analyzed mouse related RNA sequencing data. YC contributed to mouse related immunohistochemistry assays. KK contributed to the ASO injections/surgeries and to the qRT-PCR assays. AF, CM, and HK contributed to the identification and characterization of the lead ASOs. BX, contributed to the generation and initial characterization of human iPSC lines as well as the design of the human neuron-related assays. RJS provided patient referrals. SM contributed to the generation and initial characterization of human iPSC lines. JAG contributed to the conception, design and supervision of the study; PT, ML, SR, BX, SM, and JAG. contributed to the preparation of the manuscript with input from all authors.

Funding:

This work was supported by National Institute of Mental Health Grant (2R01MH097879) and a Columbia University Translational Therapeutics Pilot Award to J.A.G. This research used the service of the Columbia Genome Center (Genomics and High Throughput Screening Shared Resource), that was funded in part through the NIH/NCI Cancer Center Support Grant P30CA013696 .

Disclosure of biomedical financial interests and potential conflicts of interest:

The authors declare that they have no conflict of interest.

Data availability:

The sequencing data described in this manuscript were deposited into the Gene Expression Omnibus database under accession number GSE236596 and are available at the following URL: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE236596.

References

1. S. Morrison *et al.*, Cognitive deficits in childhood, adolescence and adulthood in 22q11.2 deletion syndrome and association with psychopathology. *Transl Psychiatry* **10**, 53 (2020).
2. M. Woodin *et al.*, Neuropsychological profile of children and adolescents with the 22q11.2 microdeletion. *Genet Med* **3**, 34-39 (2001).
3. K. L. McCabe *et al.*, Divergent patterns of social cognition performance in autism and 22q11.2 deletion syndrome (22q11DS). *J Autism Dev Disord* **43**, 1926-1934 (2013).
4. B. Xu *et al.*, Strong association of de novo copy number mutations with sporadic schizophrenia. *Nat Genet* **40**, 880-885 (2008).
5. K. L. Stark *et al.*, Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model. *Nat Genet* **40**, 751-760 (2008).
6. R. A. Piskorowski *et al.*, Age-Dependent Specific Changes in Area CA2 of the Hippocampus and Social Memory Deficit in a Mouse Model of the 22q11.2 Deletion Syndrome. *Neuron* **89**, 163-176 (2016).
7. B. Xu, P. K. Hsu, K. L. Stark, M. Karayiorgou, J. A. Gogos, Derepression of a neuronal inhibitor due to miRNA dysregulation in a schizophrenia-related microdeletion. *Cell* **152**, 262-275 (2013).
8. R. I. Gregory *et al.*, The Microprocessor complex mediates the genesis of microRNAs. *Nature* **432**, 235-240 (2004).
9. Z. Sun, D. J. Williams, B. Xu, J. A. Gogos, Altered function and maturation of primary cortical neurons from a 22q11.2 deletion mouse model of schizophrenia. *Transl Psychiatry* **8**, 85 (2018).
10. R. Saito *et al.*, Comprehensive analysis of a novel mouse model of the 22q11.2 deletion syndrome: a model with the most common 3.0-Mb deletion at the human 22q11.2 locus. *Transl Psychiatry* **10**, 35 (2020).
11. A. Guna, N. Volkmar, J. C. Christianson, R. S. Hegde, The ER membrane protein complex is a transmembrane domain insertase. *Science* **359**, 470-473 (2018).
12. P. J. Chitwood, S. Juszkiewicz, A. Guna, S. Shao, R. S. Hegde, EMC Is Required to Initiate Accurate Membrane Protein Topogenesis. *Cell* **175**, 1507-1519 e1516 (2018).
13. M. Richard, T. Boulin, V. J. Robert, J. E. Richmond, J. L. Bessereau, Biosynthesis of ionotropic acetylcholine receptors requires the evolutionarily conserved ER membrane complex. *Proc Natl Acad Sci U S A* **110**, E1055-1063 (2013).
14. T. Satoh, A. Ohba, Z. Liu, T. Inagaki, A. K. Satoh, dPob/EMC is essential for biosynthesis of rhodopsin and other multi-pass membrane proteins in Drosophila photoreceptors. *Elife* **4**, (2015).
15. P. W. Bircham *et al.*, Secretory pathway genes assessed by high-throughput microscopy and synthetic genetic array analysis. *Mol Biosyst* **7**, 2589-2598 (2011).
16. R. J. Louie *et al.*, A yeast phenomic model for the gene interaction network modulating CFTR-DeltaF508 protein biogenesis. *Genome Med* **4**, 103 (2012).
17. M. J. Shurtleff *et al.*, The ER membrane protein complex interacts cotranslationally to enable biogenesis of multipass membrane proteins. *Elife* **7**, (2018).
18. S. Tian *et al.*, Proteomic Analysis Identifies Membrane Proteins Dependent on the ER Membrane Protein Complex. *Cell Rep* **28**, 2517-2526 e2515 (2019).

19. A. Diamantopoulou *et al.*, Loss-of-function mutation in Mirta22/Emc10 rescues specific schizophrenia-related phenotypes in a mouse model of the 22q11.2 deletion. *Proc Natl Acad Sci U S A* **114**, E6127-E6136 (2017).
20. Y. Qi *et al.*, Combined small-molecule inhibition accelerates the derivation of functional cortical neurons from human pluripotent stem cells. *Nat Biotechnol* **35**, 154-163 (2017).
21. S. Siegert *et al.*, The schizophrenia risk gene product miR-137 alters presynaptic plasticity. *Nat Neurosci* **18**, 1008-1016 (2015).
22. K. T. Thomas *et al.*, Inhibition of the Schizophrenia-Associated MicroRNA miR-137 Disrupts Nrg1alpha Neurodevelopmental Signal Transduction. *Cell Rep* **20**, 1-12 (2017).
23. G. M. Schratt *et al.*, A brain-specific microRNA regulates dendritic spine development. *Nature* **439**, 283-289 (2006).
24. R. Fiore *et al.*, Mef2-mediated transcription of the miR379-410 cluster regulates activity-dependent dendritogenesis by fine-tuning Pumilio2 protein levels. *EMBO J* **28**, 697-710 (2009).
25. L. Rago, R. Beattie, V. Taylor, J. Winter, miR379-410 cluster miRNAs regulate neurogenesis and neuronal migration by fine-tuning N-cadherin. *EMBO J* **33**, 906-920 (2014).
26. M. Lackinger *et al.*, A placental mammal-specific microRNA cluster acts as a natural brake for sociability in mice. *EMBO Rep* **20**, (2019).
27. E. Gardiner *et al.*, Imprinted DLK1-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cells. *Mol Psychiatry* **17**, 827-840 (2012).
28. U. Tomasello *et al.*, miR-137 and miR-122, two outer subventricular zone non-coding RNAs, regulate basal progenitor expansion and neuronal differentiation. *Cell Rep* **38**, 110381 (2022).
29. A. J. Whipple *et al.*, Imprinted Maternally Expressed microRNAs Antagonize Paternally Driven Gene Programs in Neurons. *Mol Cell* **78**, 85-95 e88 (2020).
30. L. Chang, G. Zhou, O. Soufan, J. Xia, miRNet 2.0: network-based visual analytics for miRNA functional analysis and systems biology. *Nucleic Acids Res* **48**, W244-W251 (2020).
31. Y. Zhang *et al.*, Rapid single-step induction of functional neurons from human pluripotent stem cells. *Neuron* **78**, 785-798 (2013).
32. F. Yi *et al.*, Autism-associated SHANK3 haploinsufficiency causes Ih channelopathy in human neurons. *Science* **352**, aaf2669 (2016).
33. S. M. Ho *et al.*, Rapid Ngn2-induction of excitatory neurons from hiPSC-derived neural progenitor cells. *Methods* **101**, 113-124 (2016).
34. C. Pak, Grieder, S., Yang, N., Zhang, Y., Wernig, M., Sudhof, T., Rapid generation of functional and homogeneous excitatory human forebrain neurons using Neurogenin-2 (Ngn2). *Nature Protocol Exchange*, (2018).
35. S. B. Rao *et al.*, Aberrant pace of cortical neuron development in brain organoids from patients with 22q11.2 deletion syndrome and schizophrenia. *bioRxiv*, (2023).
36. K. D. Wilson *et al.*, MicroRNA profiling of human-induced pluripotent stem cells. *Stem Cells Dev* **18**, 749-758 (2009).
37. A. L. B. M. Soutschek, S. Galkin, T. Wüst, D.Colameo, T. Germade, F. Gross, L. v. Ziegler, J. Bohacek, P.L. Germain, J. Winterer, T. Kleele, G.M. Schratt, A human-specific microRNA controls the timing of excitatory synaptogenesis. *bioRxiv*, (2023).

38. T. A. Khan *et al.*, Neuronal defects in a human cellular model of 22q11.2 deletion syndrome. *Nat Med* **26**, 1888-1898 (2020).
39. Z. Shao *et al.*, Dysregulated protocadherin-pathway activity as an intrinsic defect in induced pluripotent stem cell-derived cortical interneurons from subjects with schizophrenia. *Nat Neurosci* **22**, 229-242 (2019).
40. A. O'Leary *et al.*, Behavioural and functional evidence revealing the role of RBFOX1 variation in multiple psychiatric disorders and traits. *Mol Psychiatry* **27**, 4464-4473 (2022).
41. K. Mirnics, F. A. Middleton, G. D. Stanwood, D. A. Lewis, P. Levitt, Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. *Mol Psychiatry* **6**, 293-301 (2001).
42. H. A. Erdely, C. A. Tamminga, R. C. Roberts, M. W. Vogel, Regional alterations in RGS4 protein in schizophrenia. *Synapse* **59**, 472-479 (2006).
43. N. Volkmar *et al.*, The ER membrane protein complex promotes biogenesis of sterol-related enzymes maintaining cholesterol homeostasis. *J Cell Sci* **132**, (2019).
44. M. L. Donegan *et al.*, Coding of social novelty in the hippocampal CA2 region and its disruption and rescue in a 22q11.2 microdeletion mouse model. *Nat Neurosci* **23**, 1365-1375 (2020).
45. L. A. Becker *et al.*, Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. *Nature* **544**, 367-371 (2017).
46. S. L. DeVos *et al.*, Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. *Sci Transl Med* **9**, (2017).
47. H. B. Kordasiewicz *et al.*, Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. *Neuron* **74**, 1031-1044 (2012).
48. V. A. Korobeynikov, A. K. Lyashchenko, B. Blanco-Redondo, P. Jafar-Nejad, N. A. Shneider, Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. *Nat Med* **28**, 104-116 (2022).
49. D. R. Scoles *et al.*, Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. *Nature* **544**, 362-366 (2017).
50. Y. Sztainberg *et al.*, Reversal of phenotypes in MECP2 duplication mice using genetic rescue or antisense oligonucleotides. *Nature* **528**, 123-126 (2015).
51. S. J. Tabrizi, A. V. Smith, C. F. Bennett, Targeting Huntingtin in Patients with Huntington's Disease. Reply. *N Engl J Med* **381**, 1181-1182 (2019).
52. A. M. Winkelsas, K. H. Fischbeck, Nucleic acid therapeutics in neurodevelopmental disease. *Curr Opin Genet Dev* **65**, 112-116 (2020).
53. C. Rinaldi, M. J. A. Wood, Antisense oligonucleotides: the next frontier for treatment of neurological disorders. *Nat Rev Neurol* **14**, 9-21 (2018).
54. B. Langmead, C. Trapnell, M. Pop, S. L. Salzberg, Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol* **10**, R25 (2009).
55. A. Tripathi *et al.*, Cognition- and circuit-based dysfunction in a mouse model of 22q11.2 microdeletion syndrome: effects of stress. *Transl Psychiatry* **10**, 41 (2020).
56. N. Paranjape *et al.*, A CRISPR-engineered isogenic model of the 22q11.2 A-B syndromic deletion. *Sci Rep* **13**, 7689 (2023).
57. M. Benger, M. Kinali, N. D. Mazarakis, Autism spectrum disorder: prospects for treatment using gene therapy. *Mol Autism* **9**, 39 (2018).

58. Y. Shao *et al.*, Antisense oligonucleotide therapy in a humanized mouse model of MECP2 duplication syndrome. *Sci Transl Med* **13**, (2021).
59. R. Kaiyrzhanov *et al.*, Biallelic loss of EMC10 leads to mild to severe intellectual disability. *Ann Clin Transl Neurol* **9**, 1080-1089 (2022).
60. D. D. Shao *et al.*, A recurrent, homozygous EMC10 frameshift variant is associated with a syndrome of developmental delay with variable seizures and dysmorphic features. *Genet Med* **23**, 1158-1162 (2021).
61. M. Umair *et al.*, EMC10 homozygous variant identified in a family with global developmental delay, mild intellectual disability, and speech delay. *Clin Genet* **98**, 555-561 (2020).
62. K. J. Karczewski *et al.*, The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* **581**, 434-443 (2020).
63. J. G. Wideman, The ubiquitous and ancient ER membrane protein complex (EMC): tether or not? *F1000Res* **4**, 624 (2015).
64. J. Mukai *et al.*, Recapitulation and Reversal of Schizophrenia-Related Phenotypes in Setd1a-Deficient Mice. *Neuron* **104**, 471-487 e412 (2019).
65. Z. S. Cheruvallath, D. L. Cole, V. T. Ravikumar, A novel solid support for synthesis of oligonucleotide 3'-phosphorothioate monoesters. *Bioorg Med Chem Lett* **13**, 281-284 (2003).
66. R. A. McKay *et al.*, Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression. *J Biol Chem* **274**, 1715-1722 (1999).
67. O. L. Barreto-Chang, R. E. Dolmetsch, Calcium imaging of cortical neurons using Fura-2 AM. *J Vis Exp*, (2009).
68. Y. Li *et al.*, Investigation of Neurodevelopmental Deficits of 22 q11.2 Deletion Syndrome with a Patient-iPSC-Derived Blood-Brain Barrier Model. *Cells* **10**, (2021).
69. M. Lin *et al.*, Integrative transcriptome network analysis of iPSC-derived neurons from schizophrenia and schizoaffective disorder patients with 22q11.2 deletion. *BMC Syst Biol* **10**, 105 (2016).
70. N. Fusaki, H. Ban, A. Nishiyama, K. Saeki, M. Hasegawa, Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. *Proc Jpn Acad Ser B Phys Biol Sci* **85**, 348-362 (2009).
71. M. Riera *et al.*, Generation of two iPS cell lines (FRIMOi003-A and FRIMOi004-A) derived from Stargardt patients carrying ABCA4 compound heterozygous mutations. *Stem Cell Res* **36**, 101389 (2019).
72. T. J. Cradick, P. Qiu, C. M. Lee, E. J. Fine, G. Bao, COSMID: A Web-based Tool for Identifying and Validating CRISPR/Cas Off-target Sites. *Mol Ther Nucleic Acids* **3**, e214 (2014).
73. D. Hockemeyer *et al.*, A drug-inducible system for direct reprogramming of human somatic cells to pluripotency. *Cell Stem Cell* **3**, 346-353 (2008).
74. S. M. Ho *et al.*, Evaluating Synthetic Activation and Repression of Neuropsychiatric-Related Genes in hiPSC-Derived NPCs, Neurons, and Astrocytes. *Stem Cell Reports* **9**, 615-628 (2017).

75. J. C. Brenes *et al.*, Differential effects of social and physical environmental enrichment on brain plasticity, cognition, and ultrasonic communication in rats. *J Comp Neurol* **524**, 1586-1607 (2016).
76. J. Mukai *et al.*, Palmitoylation-dependent neurodevelopmental deficits in a mouse model of 22q11 microdeletion. *Nat Neurosci* **11**, 1302-1310 (2008).
77. S. L. Wearne *et al.*, New techniques for imaging, digitization and analysis of three-dimensional neural morphology on multiple scales. *Neuroscience* **136**, 661-680 (2005).
78. H. Peng, Z. Ruan, F. Long, J. H. Simpson, E. W. Myers, V3D enables real-time 3D visualization and quantitative analysis of large-scale biological image data sets. *Nat Biotechnol* **28**, 348-353 (2010).
79. H. Peng, A. Bria, Z. Zhou, G. Iannello, F. Long, Extensible visualization and analysis for multidimensional images using Vaa3D. *Nat Protoc* **9**, 193-208 (2014).
80. H. Peng *et al.*, Virtual finger boosts three-dimensional imaging and microsurgery as well as terabyte volume image visualization and analysis. *Nat Commun* **5**, 4342 (2014).
81. A. M. Kopec, P. D. Rivera, M. J. Lacagnina, R. Hanamsagar, S. D. Bilbo, Optimized solubilization of TRIzol-precipitated protein permits Western blotting analysis to maximize data available from brain tissue. *J Neurosci Methods* **280**, 64-76 (2017).
82. A. Dobin *et al.*, STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15-21 (2013).
83. M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).
84. M. Martin, Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet.journal*, (2011).
85. D. Kim, B. Langmead, S. L. Salzberg, HISAT: a fast spliced aligner with low memory requirements. *Nat Methods* **12**, 357-360 (2015).
86. M. Pertea *et al.*, StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. *Nat Biotechnol* **33**, 290-295 (2015).
87. M. D. Robinson, D. J. McCarthy, G. K. Smyth, edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139-140 (2010).
88. U. Raudvere *et al.*, g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). *Nucleic Acids Res* **47**, W191-W198 (2019).
89. V. Agarwal, G. W. Bell, J. W. Nam, D. P. Bartel, Predicting effective microRNA target sites in mammalian mRNAs. *Elife* **4**, (2015).
90. S. E. McGeary *et al.*, The biochemical basis of microRNA targeting efficacy. *Science* **366**, (2019).
91. N. L. Bray, H. Pimentel, P. Melsted, L. Pachter, Near-optimal probabilistic RNA-seq quantification. *Nat Biotechnol* **34**, 525-527 (2016).
92. S. Babicki *et al.*, Heatmapper: web-enabled heat mapping for all. *Nucleic Acids Res* **44**, W147-153 (2016).
93. S. Kumar, D. T. Sarmah, S. Asthana, S. Chatterjee, konnect2prot: a web application to explore the protein properties in a functional protein-protein interaction network. *Bioinformatics* **39**, (2023).
94. A. K. Kraeuter, P. C. Guest, Z. Sarnyai, The Y-Maze for Assessment of Spatial Working and Reference Memory in Mice. *Methods Mol Biol* **1916**, 105-111 (2019).

Figure Legends

Fig. 1. EMC10 is robustly upregulated in hiPSC-derived neurons from 22q11.2 deletion carriers. (A) Schematic diagram depicting the human chromosome 22q11.2 region. Bright grey and red horizontal bars indicate the two most common hemizygous genomic deletions found in the 22q11.2 deletion syndrome. The location of the coding genes and non-coding RNAs (miRNAs, underlined) are shown for chromosome 22q11.2. The microprocessor *DGCR8* (DiGeorge Syndrome Critical Region Gene 8) and *mir185* are shown in bold. **(B)** Cortical marker TBR1 and pan-neuronal marker TUJ1 expression in cortical neurons as detected by immunocytochemistry at day 13 of differentiation. TBR1 (red), TUJ1 (green) and DAPI (blue) expression are shown. Scale bars: 100 µm. **(C)** Volcano plot showing differentially expressed miRNAs (DEmiRs) in cortical neurons at day 8 of differentiation. Significant DEmiRs (P value < 5%) are shown above red line; Q5 (Ctrl) n=3, Q6 (22q11.2) n=3. 153/133 miRNAs were significantly up- and downregulated in Q6 (22q11.2) hiPSC-derived cortical neurons, respectively. 22q11.2 deletion region residing miRNAs miR-185, miR-1286 and miR-1306 are highlighted. **(D-F)** Consistent upregulation of *EMC10* mRNA in Q6 (22q11.2) line derived cortical neurons as assayed by qRT-PCR at **(D)** day 8 (P= 0.031; Q5: n=3, Q6: n=3), **(E)** day 20 (P= 0.0478; Q5: n=4, Q6: n=4) and **(F)** day 34 (P= 0.0358; Q5: n=3, Q6: n=3) of differentiation. **(G)** Western blot analysis showing upregulated EMC10 protein levels in Q6 (22q11.2) line derived cortical neurons at day 8 of differentiation. Tubulin was probed as a loading control. **(H)** Immunofluorescence images of NGN2 generated cells. Representative images of NGN2-iNs at DIV21 from Q5 (Ctrl) and Q6 (22q11.2) hiPSC lines identified via EGFP fluorescence and immunostained for neuronal dendrite marker MAP2 and the nuclear marker DAPI. Scale bars=100 µm. **(I-K)** qRT-PCR assay of *EMC10* mRNA expression level in NGN2-iNs at DIV21. **(I)** Upregulation of *EMC10* mRNA in Q6 (22q11.2) line derived neurons compared to the healthy control line Q5 (P=0.0222). Q5 (Ctrl) n=4, Q6 (22q11.2) n=4. **(J)** Upregulation of *EMC10* mRNA in Q1 (22q11.2) patient line compared to healthy control line Q2 (P=0.0441). Q2 (Ctrl) n=5 and Q1 (22q11.2) n=7. **(K)** Upregulation of

EMC10 mRNA in QR27 (22q11.2) patient line compared to healthy control line QR20 (P=0.0414). QR20 (Ctrl) n=5 and QR27 (22q11.2) n=5. Data are presented as mean ±SEM, unpaired two-tailed t-test, *P<0.05, **P<0.01.

Fig. 2. Altered miRNA expression in hiPSC-derived cortical neurons from 22q11.2 deletion carriers. (A) Precursor miRNA expression level of miR-185 (P= 0.0038), predicted to target *EMC10*, are downregulated in Q6 (22q11.2) cortical neurons as assayed by qRT-PCR (Q5: n=3, Q6: n=3). **(B)** Precursor miRNA expression level of miR-485 (P= 0.0622), predicted to target *EMC10*, are downregulated in Q6 (22q11.2) cortical neurons as assayed by qRT-PCR (Q5: n=3, Q6: n=3). **(C-E)** miR-185 and miR-485 modulate *EMC10* in human iPSC-derived cortical neurons. **(C)** qRT-PCR quantification shows reduced expression levels of *EMC10* mRNA in Q5 (Ctrl) line derived cortical neurons at day 10 of differentiation transfected with miR-185 [one-way ANOVA, F (2, 6) = 6.079 , P=0.0361; post hoc Bonferroni, P=0.0366] or miR-485 [post hoc Bonferroni, P=0.0464] mimics at day 8 of differentiation. Expression levels in miR-185 or miR-485 mimic-treated neurons were normalized to expression levels under scramble mimic controls treatment (n= 3, each treatment). **(D)** qRT-PCR quantification shows reduced expression levels of *EMC10* mRNA in Q6 line-derived cortical neurons transfected with miR-185 [one-way ANOVA, F (3, 13) = 7.167 , P=0.0044; post hoc Tukey, P=0.0345] or miR-485 [post hoc Tukey, P=0.0251] or a combination of both miRNA mimics [post hoc Tukey, P=0.0020]. Expression levels in miR-185, miR-485 or the combination of both mimic-treated neurons were normalized to expression levels under scramble mimic controls treatment. Ctrl mimic n=5, miR-185 mimic n=5, miR-485 mimic n=4 and miR185+miR485 mimics n=3. **(E)** qRT-PCR quantification shows increased expression levels of *EMC10* mRNA in Q5 line derived cortical neurons transfected with miRNA inhibitors miR-185 [one-way ANOVA, F (2, 6) = 11.94 , P=0.0081; post hoc Bonferroni, P=0.0057]or miR-485 [post hoc Bonferroni, P=0.0491] at day 8 of differentiation. Expression levels in miR-185 or miR-485 inhibitor-treated neurons were normalized to expression levels under scramble miRNA

inhibitor controls treatment (n=3, each treatment). Data are presented as mean ±SEM, unpaired two-tailed t-test or one-way ANOVA as indicated, *P<0.05, **P<0.01.

Fig. 3. Reduction of *EMC10 levels* restores defects in neurite outgrowth and calcium signaling in neurons from 22q11.2 deletion carriers. **(A)** Representative images of NGN2-iNs at DIV21 from Q6/EMC10^{HET} and Q6/EMC10^{HOM} hiPSC lines identified via EGFP fluorescence and immunostained for neuronal dendrite marker MAP2 and the nuclear marker DAPI. Scale bars=50 µm. **(B)** qRT-PCR assay of *EMC10* mRNA expression level in NGN2-iNs at DIV21. *EMC10* expression is normalized to near WT levels level in Q6/EMC10^{HET} line (P=0.166) and abolished in Q6/EMC10^{HOM} line (P<0.0001). Q5 (Ctrl) n=4, Q6 (22q11.2/SCZ) n=4, Q6/EMC10^{HET} n=5 and Q6/EMC10^{HOM} n=7. **(C-G)** Neuronal morphology analysis in Q5, Q6 (22q11.2), Q6/EMC10^{HET} and Q6/EMC10^{HOM} neurons. **(C)** Representative images of traced neurons. **(D)** Total neuronal length is reduced in Q6 line (P=0.0044) and restored in Q6/ EMC10^{HET} (P=0.0253) and Q6/EMC10^{HOM} line (P=0.0001). **(E)** Reduction in number of branch points/cell in Q6 (P=0.0195) is restored in the Q6/EMC10^{HET} (P=0.0134) and Q6/EMC10^{HOM} lines (P<0.0001). **(F)** Reduction in the total number of dendrites/cells in Q6 (P=0.0202) is reversed in the Q6/EMC10^{HET} (P=0.0166) and Q6/EMC10^{HOM} lines (P=0.0005) **(G)** The number of primary dendrites per cell is unchanged. Q5 (Ctrl) n=14, Q6 (22q11.2) n=16, Q6/EMC10^{HET} n=19 and Q6/EMC10^{HOM} n=16 neuronal cells. **(H-I)** Defects in cytoplasmic calcium signaling in Q6 (22q11.2) neurons are reversed in Q6/EMC10^{HET} and Q6/EMC10^{HOM} lines. **(H)** Changes in Fluo4-AM fluorescence signal intensity in response to 75mM KCl in Q5 (Ctrl), Q6 (22q11.2). Q6/EMC10^{HET} and Q6/EMC10^{HOM} hiPSC-derived neurons at DIV38. Q5 vs. Q6 (KS D=0.5405, P<0.0001), Q6 vs. Q6 EMC10^{HET} (KS D=0.5556, P<0.0001) and Q6 vs. Q6 EMC10^{HOM} (KS D=0.5676, P<0.0001). **(I)** Quantification of KCl-induced Fluo4 intensity peak amplitude (ΔF) demonstrates a reduction in Q6 line (P<0.0001) that is reversed in Q6/EMC10^{HET} (P<0.0001) and Q6/EMC10^{HOM} lines (P<0.0001). Q5 (Ctrl) n=70, Q6 (22q11.2/SCZ) n=37, Q6/EMC10^{HET} n=82, Q6/EMC10^{HOM} n=97 neuronal cells. **(J)**

Heatmap (left) showing the expression of differentially regulated 237 genes in Q5 (Ctrl) and Q6 (22q11.2) that are normalized in the Q6/EMC10^{HET} NGN2-iNs at DIV21 (n=3 per genotype). Gene Ontology (GO) biological process (BP) terms (right) associated with the up- and down-regulated genes normalized in the Q6/EMC10^{HET} NGN2-iNs. **(K)** Heatmap (left) showing the expression of differentially regulated 382 genes in Q5 (Ctrl) and Q6 (22q11.2) that are normalized in the Q6/EMC10^{HOM} NGN2-iNs at DIV21 (n=3 per genotype). Gene Ontology (GO) biological process (BP) terms (right) associated with the up- and down-regulated genes normalized in the Q6/EMC10^{HOM} NGN2-iNs. Data are presented as mean ±SEM, unpaired two-tailed t-test or Kolmogorov–Smirnov test as indicated, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

Fig. 4. ASO-mediated suppression of murine *Emc10 in vivo*. (A) Mouse *Emc10* gene map plot (ENSMUST00000118808) showing the *Emc10*^{ASO1} target site. **(B)** Mouse brains collected three weeks post ICV injection were stained with an ASO antibody (green), counterstained with neuronal marker NeuN (red) and nuclear stain Hoechst (blue). A robust and uniform ASO diffusion (top panel) is observed in the HPC. No signal is detected in saline injected mice (bottom panel). Overlap with NeuN (yellow, top-right panel) confirms presence in neuronal cells. Accumulation in glial cells, specifically GFAP labeled astrocytes is also observed (middle-right panel and inset; ASO in green, GFAP in red, and Hoechst in blue). Images are taken with 4x, 20x and 40x objectives. (**C)** qRT-PCR analysis shows Emc10^{ASO} meditated normalization of *Emc10* mRNA levels in the HPC of *Df(16)A*$^{+/-}$ mice (left panel). Significant upregulation of *Emc10* mRNA expression levels is seen in Ctrl^{ASO} treated-*Df(16)A*$^{+/-}$ compared to WT mice [one-way ANOVA, F (2, 29) = 11.65, P<0.001; post hoc Tukey, P= 0.001]. Following ASO treatment, *Emc10* expression is normalized to WT levels in Emc10^{ASO} treated-*Df(16)A*$^{+/–}$ compared to Ctrl^{ASO} treated-*Df(16)A*$^{+/-}$ mice (post hoc Tukey, P= <0.001). Ctrl^{ASO}-treated WT mice: n=9 (5 males, 4 females), Ctrl^{ASO}-treated *Df(16)A*$^{+/}$ mice: n=11 (5 males, 6 females), and Emc10^{ASO}-treated *Df(16)A*$^{+/}$ mice: n=12 (7 males, 5 females). qRT-PCR analysis shows a significant up-regulation of *Emc10* mRNA

expression levels in the PFC of Ctrl^{ASO} treated-*Df(16)A*$^{+/-}$ (right panel) compared to WT mice [one-way ANOVA, F (2, 16) = 4.253, P=0.0330; post hoc Tukey, P= 0.0385]. ASO injection does not normalize *Emc10* expression levels in PFC of *Df(16)A*$^{+/}$ mice injected with Emc10^{ASO} (post hoc Tukey vs Ctrl^{ASO} treated *Df(16)A*$^{+/}$ mice, P= 0.7642). Ctrl^{ASO} treated-WT male mice: n=6, Ctrl^{ASO} treated-*Df(16)A*$^{+/-}$ male mice: n=5, and Emc10^{ASO} treated-*Df(16)A*$^{+/}$ male mice: n=8. **(D)** Volcano plots showing up-regulation of *Emc10* expression in the Ctrl^{ASO} treated-*Df(16)A*$^{+/-}$ compared to the Ctrl^{ASO}-treated WT mice (left panel and inset) but not in the Emc10^{ASO} treated-*Df(16)A*$^{+/-}$ compared to the Emc10^{ASO}-treated WT mice (right panel and inset). The expected down-regulation of genes included in the *Df(16)A*$^{+/–}$ deletion (blue) and upregulation of non-coding RNAs (ncRNAs, red) is also evident in both panels. Downregulated genes from the 22q11.2 locus (*Dgcr8*, *Ranbp1* and *Tango2*) as well as the upregulated ncRNA (miRNA-containing) gene *Mirg*, are highlighted. Ctrl^{ASO} treated-*Df(16)A*$^{+/–}$ males: n=5, Emc10^{ASO} treated-*Df(16)A*$^{+/–}$ males: n= 4, Ctrl^{ASO} treated WT males: n=4, and Emc10^{ASO} treated-WT males: n=4. **(E-F)** ASO mediated behavioral rescue of SM deficit in *Df(16)A*$^{+/-}$ mice. **(E)** Ctrl^{ASO}-treated *Df(16)A*$^{+/-}$ mice show a robust SM deficit compared to Ctrl^{ASO}-treated WT mice as indicated by the significant difference in trial 2 interaction time upon reintroduction of a familiar juvenile mouse [three-way ANOVA for Trial X Genotype X Treatment Interaction matching by trial: F (1, 38) = 9.393 P=0.0040; post hoc Tukey, P= 0.0012]. A reduction in trial 2 interaction time indicates rescue of the SM deficit in Emc10^{ASO}-treated *Df(16)A*$^{+/-}$ compared to Ctrl^{ASO}-treated *Df(16)A*$^{+/-}$ mice (post hoc Tukey, P= 0.0114). **(F)** A negative difference score (trial 1- trial 2) confirms the SM deficit in Ctrl^{ASO}-treated adult *Df(16)A*$^{+/-}$ mice compared to WT littermates [two-way ANOVA for Genotype X Treatment interaction: F (1, 38) =9.369, P=0.0040; post hoc Tukey, P= 0.0002]. Increase in the difference score of *Df(16)A*$^{+/-}$ mice in the Emc10^{ASO}- vs Ctrl^{ASO}- treated group demonstrates SM rescue (post hoc Tukey, P= 0.0004). [Ctrl^{ASO}-treated WT mice: n=9 (5 males, 4 females), Ctrl^{ASO}-treated *Df(16)A*$^{+/}$ mice: n=11 (5 males, 6 females), Emc10^{ASO} treated WT mice: n=9 (5 males, 4 females),

and Emc10^{ASO}-treated *Df(16)A*$^{+/}$ mice: n=13 (7 males, 6 females)]. Data are presented as mean ± SEM, *P < 0.05; **P < 0.01; ***P < 0.001.

Figure 5: Restoration of cognitive function in *Df(16)A*$^{+/-}$ mice using an independent *Emc10* ASO. (A) Mouse *Emc10* gene map plot (ENSMUST00000118808) showing the Emc10^{ASO2} target site. **(B)** qRT-PCR analysis shows significant upregulation of *Emc10* mRNA expression levels in the HPC of Ctrl^{ASO} treated-*Df(16)A*$^{+/-}$ compared to WT mice [one-way ANOVA, F (2, 19) = 20.92, P<0.0001; post hoc Tukey, P= 0.0018]. Following ASO treatment, *Emc10* expression is normalized to WT levels in Emc10^{ASO} treated-*Df(16)A*$^{+/–}$ compared to Ctrl^{ASO} treated-*Df(16)A*$^{+/-}$ mice (post hoc Tukey, P= <0.0001). **(C)** qRT-PCR analysis shows a significant up-regulation of *Emc10* mRNA expression levels in the PFC of Ctrl^{ASO} treated-*Df(16)A*$^{+/-}$ compared to WT mice [one-way ANOVA, F (2, 19) = 40.75, P=<0.0001; post hoc Tukey, P=<0.0001]. Following ASO treatment, *Emc10* expression is normalized to WT levels in the Emc10^{ASO} treated-*Df(16)A*$^{+/–}$ compared to Ctrl^{ASO} treated-*Df(16)A*$^{+/-}$ mice (post hoc Tukey, P=<0.0001). Ctrl^{ASO}-treated WT male mice: n=6, Ctrl^{ASO}-treated *Df(16)A*$^{+/}$ male mice: n=8, and Emc10^{ASO}-treated *Df(16)A*$^{+/}$ mice: n=8. **(D)** qRT-PCR analysis shows a significant up-regulation of *Emc10* mRNA expression levels in Somatosensory Cortex (SSC) of Ctrl^{ASO} treated-*Df(16)A*$^{+/-}$ compared to WT mice [one-way ANOVA, F (2, 18) = 21.53, P=<0.0001; post hoc Tukey, P=<0.0026]. Following ASO treatment, *Emc10* expression is normalized to WT levels in Emc10^{ASO} treated-*Df(16)A*$^{+/–}$ compared to Ctrl^{ASO} treated-*Df(16)A*$^{+/-}$ mice (post hoc Tukey, P=<0.0001). Ctrl^{ASO}-treated WT mice: n=6, Ctrl^{ASO}-treated *Df(16)A*$^{+/}$ mice: n=7, and Emc10^{ASO}-treated *Df(16)A*$^{+/}$ mice: n=8. **(E)** Ctrl^{ASO}-treated *Df(16)A*$^{+/-}$ mice show a robust SM deficit compared to Ctrl^{ASO}-treated WT mice as indicated by the significant difference in trial 2 interaction time upon reintroduction of a familiar juvenile mouse [three-way ANOVA for Trial X Genotype X Treatment Interaction matching by trial: F (1, 26) = 35.74 P<0.0001; post hoc Tukey, P= 0.0004]. A reduction in trial 2 interaction time indicates rescue of the SM deficit in Emc10^{ASO}-treated *Df(16)A*$^{+/-}$ compared to Ctrl^{ASO}-treated *Df(16)A*$^{+/-}$

mice (post hoc Tukey, P= 0.0255). [Ctrl^{ASO}-treated WT male mice: n=6, Ctrl^{ASO}-treated *Df(16)A*$^{+/}$ mice: n=8, Emc10^{ASO} treated WT mice: n=8, and Emc10^{ASO}-treated *Df(16)A*$^{+/}$ mice: n=8. **(F)** A negative difference score (trial 1- trial 2) confirms the SM deficit in Ctrl^{ASO}-treated adult *Df(16)A*$^{+/-}$ mice compared to WT littermates [two-way ANOVA for Genotype X Treatment interaction F (1, 26) = 35.74, P<0.0001; post hoc Tukey, P<0.0001. Increase in the difference score of *Df(16)A*$^{+/-}$ mice in the Emc10^{ASO}- vs Ctrl^{ASO}- treated group demonstrates SM rescue (post hoc Tukey, P<0.0001). **(G)** Y-maze task displayed memory impairments in adult *Df(16)A*$^{+/-}$ mice. Impaired short-term spatial memory in *Df(16)A*$^{+/-}$ mice shown by the reduced amount of delayed alternations (%) after a delay of 1h (P=0.0015). WT mice: n=12, *Df(16)A*$^{+/}$ mice: n=11. **(H)** Deficits in short-term spatial memory in the Y-maze task in Ctrl^{ASO}-treated adult *Df(16)A*$^{+/-}$ mice can be rescued in Emc10^{ASO}-treated *Df(16)A*$^{+/-}$ mice (one-way ANOVA, F(3, 25) = 6.727, P=0.0018, post hoc Tukey, P=0.0042) after 3-weeks of ASO-injection. Ctrl^{ASO}-treated WT mice: n=8, Emc10^{ASO} treated WT mice: n=8, Ctrl^{ASO}-treated *Df(16)A*$^{+/}$ mice: n=8 and Emc10^{ASO}-treated *Df(16)A*$^{+/}$ mice: n=5. **(I)** In a contextual fear memory assay, minimal freezing is observed on day 1 (left) with no significant changes across groups [two-way ANOVA for Genotype X Treatment interaction: F (1, 52) = 1.003, P=0.3211]. In the Ctrl^{ASO}-treated group, *Df(16)A*$^{+/-}$ mice show the expected contextual fear memory deficit compared to WT mice (right panel) [one-way ANOVA, F (3, 52) = 3.524 P=0.0212; post hoc Tukey, 0.0384]. Emc10^{ASO} treatment was not sufficient to fully rescue the learning deficit in *Df(16)A*$^{+/–}$ mice compared to Ctrl^{ASO}-treated WT levels (post hoc Tukey, P= 0.1045). However, there is increased freezing in *Df(16)A*$^{+/-}$ mice injected with Emc10^{ASO}- versus Ctrl^{ASO}-treated group, which results in a non-significant difference in freezing between Emc10^{ASO}-treated *Df(16)A*$^{+/-}$ and WT mice (two-way ANOVA for genotype x treatment F (1, 52) = 0.8524, P=0.3601; post hoc Tukey, P= 0.4676) indicating a partial rescue of the contextual fear memory deficit. Ctrl^{ASO}-treated WT: n=13 (9 males, 4 females), Emc10^{ASO} treated WT mice: n=14 (10 males, 4 females), Ctrl^{ASO}-treated *Df(16)A*$^{+/}$ mice: n=15 (11 males, 4 females and Emc10^{ASO}-treated *Df(16)A*$^{+/}$ mice: n=14 (10 males, 4 females). Unpaired students t-test, one- two- or three-

way ANOVA as indicated. Data are presented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.01, ****P<0.0001.

Figure 6: Sustained rescue of cognitive deficits in *Df(16)A*$^{+/-}$ mice following ASO administration. (A) Experimental timeline of Emc10^{ASO2}-treated adult *Df(16)A*$^{+/-}$ mice to determine long-term rescue effect of Emc10 de-repression. **(B-C)** Sustained ASO effect on behavioral rescue of Emc10^{ASO}-treated *Df(16)A*$^{+/-}$ mice in HPC- and PFC-dependent tasks. **(B)** Rescue of SM deficit in *Df(16)A*$^{+/-}$ mice after 3- and 8-weeks of ASO injection. After 3-weeks of ASO treatment (left panel), a negative difference score (trial 1- trial 2) confirms the SM deficit in Ctrl^{ASO}-treated adult *Df(16)A*$^{+/-}$ mice compared to WT littermates [two-way ANOVA for Genotype X Treatment interaction F (1, 28) = 26.20, P<0.0001; post hoc Tukey, P<0.0001]. Increase in the difference score of *Df(16)A*$^{+/-}$ mice in the Emc10^{ASO}- vs Ctrl^{ASO}- treated group demonstrates SM rescue (post hoc Tukey, P<0.0001). After 8-weeks of ASO treatment (right panel), a negative difference score (trial 1- trial 2) confirms the SM deficit in Ctrl^{ASO}-treated adult *Df(16)A*$^{+/-}$ mice compared to WT littermates [two-way ANOVA for Genotype X Treatment interaction F (1, 28) = 13.36, P=0.0010; post hoc Tukey, P=0.0012. Increase in the difference score of *Df(16)A*$^{+/-}$ mice in the Emc10^{ASO}- vs Ctrl^{ASO}- treated group demonstrates prolonged SM rescue (post hoc Tukey, P=0.0007). Ctrl^{ASO}-treated WT mice: n=9, Ctrl^{ASO}-treated *Df(16)A*$^{+/}$ mice: n=7, Emc10^{ASO}-treated WT mice: n=8 and Emc10^{ASO}-treated *Df(16)A*$^{+/}$ mice: n=8. **(C)** Y-maze task displayed rescue of memory impairments in adult *Df(16)A*$^{+/-}$ male mice 4- and 9-weeks after Emc10^{ASO} injection. Deficits in short-term spatial memory shown by the reduced number of delayed alternations (%) in Ctrl^{ASO}-treated adult *Df(16)A*$^{+/-}$ mice can be rescued in Emc10^{ASO}-treated *Df(16)A*$^{+/-}$ mice after 4-weeks of ASO injection (left panel) [one-way ANOVA, F(3, 29) = 7.585, P=0.0007, post hoc Tukey, P=0.0193]. Deficits in short-term spatial memory in Ctrl^{ASO}-treated adult *Df(16)A*$^{+/-}$ mice can be rescued in Emc10^{ASO}-treated *Df(16)A*$^{+/-}$ mice also after 9-weeks of ASO injection (right panel) [one-way ANOVA, F(3, 29) = 6.547, P=0.0016, post hoc Tukey, P=0.0029]. Ctrl^{ASO}-treated

WT mice: n=9, Ctrl^{ASO}-treated *Df(16)A*$^{+/}$ mice: n=8, Emc10^{ASO}-treated WT mice: n=8 and Emc10^{ASO}-treated *Df(16)A*$^{+/}$ mice: n=8. **(D-F)** Sustained Emc10 de-repression after two months of Emc10^{ASO} injection. ASO-mediated inhibition of *Emc10* in different brain regions of *Df(16)A*$^{+/-}$ mice after 10-weeks of injection. **(D)** qRT-PCR analysis shows significant upregulation of *Emc10* mRNA expression levels in the HPC of Ctrl^{ASO} treated-*Df(16)A*$^{+/-}$ compared to WT mice [one-way ANOVA, F (3, 29) = 13.97, P<0.0001; post hoc Tukey, P=0.0331]. Following ASO treatment, *Emc10* expression is normalized to WT levels in Emc10^{ASO} treated-*Df(16)A*$^{+/–}$ compared to Ctrl^{ASO} treated-*Df(16)A*$^{+/-}$ mice (post hoc Tukey, P= <0.0002). Ctrl^{ASO}-treated WT mice: n=9, Ctrl^{ASO}-treated *Df(16)A*$^{+/}$ mice: n=8, Emc10^{ASO}-treated WT mice: n=8 and Emc10^{ASO}-treated *Df(16)A*$^{+/}$ mice: n=8. **(E)** qRT-PCR analysis shows a significant up-regulation of *Emc10* mRNA expression levels in the PFC of Ctrl^{ASO} treated-*Df(16)A*$^{+/-}$ compared to WT mice [one-way ANOVA, F (3, 28) = 32.47 , P<0.0001; post hoc Tukey, P<0.0001]. Following ASO treatment, *Emc10* expression is normalized to WT levels in the Emc10^{ASO} treated-*Df(16)A*$^{+/–}$ compared to Ctrl^{ASO} treated-*Df(16)A*$^{+/-}$ mice (post hoc Tukey, P<0.0001). Ctrl^{ASO}-treated WT mice: n=9, Ctrl^{ASO}-treated *Df(16)A*$^{+/}$ mice: n=7, Emc10^{ASO}-treated WT mice: n=8 and Emc10^{ASO}-treated *Df(16)A*$^{+/}$ mice: n=8. **(F)** qRT-PCR analysis shows a significant up-regulation of *Emc10* mRNA expression levels in Somatosensory Cortex (SSC) of Ctrl^{ASO} treated-*Df(16)A*$^{+/-}$ compared to WT mice [one-way ANOVA, F (3, 28) =23.18, P<0.0001; post hoc Tukey, P=0.0001]. Following ASO treatment, *Emc10* expression is normalized to WT levels in Emc10^{ASO} treated-*Df(16)A*$^{+/–}$ compared to Ctrl^{ASO} treated-*Df(16)A*$^{+/-}$ mice (post hoc Tukey, P<0.0001). Ctrl^{ASO}-treated WT mice: n=9, Ctrl^{ASO}-treated *Df(16)A*$^{+/}$ mice: n=8, Emc10^{ASO}-treated WT mice: n=8 and Emc10^{ASO}-treated *Df(16)A*$^{+/}$ male mice: n=7. One- or two-way ANOVA as indicated. Data are presented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.01, ****P<0.0001.

SUPPLEMENTARY INFORMATION

Supplementary Figures

Fig. S1. Validation and characterization of hiPSCs and hiPSC-derived neurons. (A) Characterization of Q5 (Ctrl) and Q6 (22q11.2) hiPS cells demonstrate normal karyotype distribution in both lines. **(B-D)** Characterization of the Q5 and Q6 hiPSC lines. Multiplex Ligation-dependent Probe Amplification (MLPA) assay of gene copies within and around 22q11.2 locus for Q5 (Ctrl) **(B)** and Q6 (22q11.2) **(C)** line shows that copy number of genes in the 22q11.2 locus (highlighted in light blue) are reduced by half in the Q6 (22q11.2) hiPSC line. **(D)** qRT-PCR assays of embryonic stem cell marker *OCT4/POU5F1* and *NANOG* shows that they are highly expressed in both hiPSC lines (Q5 Ctrl and Q6 22q11.2). **(E)** TBR1 and TUJ1 expression of cortical neurons by immunocytochemistry at day 20 of differentiation indicates the efficiency of hiPSC differentiation into cortical neurons. TBR1 (red), TUJ1 (green) and DAPI (blue). Scale bar: 100 µm. **(F-G)** Time-course qRT-PCR analysis at day 0 and day 20 of differentiation of human pluripotency marker **(F)** *OCT4/POU5F1* (P= 0.0012) and **(G)** *TBR1* (P= 0.0273), a preplate, subplate and cortical Layer VI neuron marker in Q5 (Ctrl) line. Day 0: n=4, Day 20 n=4. Data are presented as mean ± SEM, unpaired two-tailed t-test, *P<0.05, **P<0.01.

Fig. S2: Expression profile of selected miRNAs in Q5 (Ctrl) and Q6 (22q11.2) cortical neurons at day 8 of differentiation. (A) 22q11.2 region residing miRNAs and **(B)** selected miRNAs residing outside the 22q11.2 region (Q5 n=3, Q6 n=3). Data are presented as mean ± SEM, P < 0.05.

Fig. S3: GO-term analysis of altered miRNA expression in hiPSC-derived cortical neurons with 22q11.2 deletion. (A-B) Gene Ontology (GO) term enrichment analysis of up- and down-regulated DEmiRs highlighted cell cycle and cell division relevant terms. **(A)** Biological Process. **(B)** Cellular Component.

Fig. S4: Altered gene expression in hiPSC-derived cortical neurons from 22q11.2 deletion carriers. (A) Volcano plot showing differential gene expression in cortical neurons at day 8 of differentiation. Significantly differentially expressed genes (FDR<5%) are shown above red line; Q5 (Ctrl) n=3, Q6 (22q11.2) n=3. 1937/2094 genes were significantly up- and downregulated in Q6 (22q11.2) hiPSC-derived cortical neurons, respectively. 22q11.2 deletion region residing genes *RANBP1* and *DGCR8* as well as *EMC10* are highlighted. **(B)** qRT-PCR analysis confirming reduction of *DGCR8* (P= 0.0261) and *RANBP1* (P= 0.0.0006) mRNAs but not for the housekeeping control *RPLP0* (P= 0.7155) gene at day 8 of differentiation in Q6 (22q11.2) compared to Q5(Ctrl) lines derived cortical neurons (Q5: n=3, Q6: n=3). (**C)** Western blot analysis showing reduced amount of DGCR8 and RANBP1 protein in Q6 (22q11.2) line derived cortical neurons at day 8 of differentiation. Tubulin was probed as a loading control. **(D-E)** Gene Ontology (GO) term enrichment analysis of up- and down-regulated DEGs reveals several neuronal related components. **(D)** Biological Process. **(E)** Cellular Component. **(F)** Intersection of predicted miRNA targets and gene expression analysis. Venn diagram highlighting up-regulated DEGs (from bulk RNAseq) that are predicted targets of down-regulated miRNAs (774). **(G-H)** Gene Ontology (GO) term enrichment analysis of predicted targets reveals several neuronal related components for the up-regulated genes. **(G)** Biological Process. **(H)** Cellular Component.

Fig. S5: Predicted miRNA targets. (A) Schematic of human and mouse *Emc10* 3'UTR showing miR-185 (green) and miR-485 (blue) binding sites predicted by TargetScan. Conserved target sites in mammals are marked with an asterisk. Specific binding site positions in *Emc10* 3'UTR are indicated in brackets. Human *EMC10* 3'UTR: miR-185-5p site 1* (467-474), site 2 (2807-2813), miR-485-5p site 1* (473-479), site 2 (585-591), site 3 (1530-1536), site 4 (1996-2002), site 5 (3516-3522), site 6 (4158-4164). Mouse *Emc10* 3'UTR: miR-185-5p site 1* (400-407), site 2 (454-460), miR-485-5p site 1* (406-412), site 2 (513-519), site 3 (796-802), site 4 (2842-2848), site 5 (4013-4020), site 6 (4576-4582).

Fig. S6: Characterization of hiPSC lines carrying an *EMC10* LoF mutation. (A) CRISPR/Cas9 genome editing in Q6 (22q11.2) hiPSCs to obtain *EMC10* LoF mutation lines. Two 20bp guided RNAs (gRNAs) were designed to specifically target the *EMC10* exon 3 region (transcript 201, ENNST00000334976.11), to generate a frameshift mutation as indicated by the green (EMC10-g1) and blue (EMC10-g2) arrow in the gRNA profiles at *EMC10* locus (**Fig. S6A**, upper panel). Upper panel (**Fig. S6A**): gRNA design and profile at the targeted *EMC10* locus that leads to frameshift mutations. Lower panel **(Fig. S6A)**: Genotyping of positive clones for Q6/EMC10^{HET} and Q6/EMC10^{HOM} lines confirms frameshift mutation. **(B)** Characterization of Q6/EMC10^{HET} and Q6/EMC10^{HOM} hiPS cells demonstrate normal karyotype distribution **(C-G)** Western Blot assay and qRT-PCR assays in hiPSC lines. **(C)** Western blot analysis confirmed reduction of RANBP1 protein levels in Q6, Q6/EMC10^{HET} and Q6/EMC10^{HOM} lines. Embryonic stem cell marker **(D)** *NANOG* and **(E)** *OCT4/POU5F1* are highly expressed in all four hiPSC lines assayed. **(F)** qRT-PCR assay in hiPSC lines. *EMC10* expression is reduced or abolished in Q6/EMC10^{HET} line (P=0.0002) and Q6/EMC10^{HOM} line (P=0.0003), respectively, when compared to Q5 (Ctrl) line. Note that *EMC10* is not upregulated in Q6 hiPSCs. Q5 (Ctrl) n=5, Q6 (22q11.2) n=5, Q6/EMC10^{HET} n=6 and Q6/EMC10^{HOM} n=4. **(G)** Western blot analysis showing reduction (Q6/EMC10^{HET}) or elimination (Q6/EMC10^{HOM}) of EMC10 protein levels in the *EMC10* LoF mutant hiPSC lines. Tubulin was probed as a loading control**.** **(H)** qRT-PCR assay of neuronal differentiation (*NEUROD1*), excitatory (*vGLUT1*) and cortical projection (*BRN2*) markers demonstrating similar mRNA expression pattern in Q6 (22q11.2) and derivative Q6/EMC10^{HET} and Q6/EMC10^{HET} NGN2-iNs at DIV21 whereas the glia marker *GFAP* and the inhibitory marker *DLX1* were not detected. Q6 (22q11.2) n=3-5, Q6/EMC10^{HET} n=3-6, Q6/EMC10^{HOM} n=3-5. Data are presented as mean ± SEM, unpaired two-tailed t-test, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

Fig. S7: Defects in cytoplasmic calcium signaling in Q6 (22q11.2) neurons. (A) Changes in Fluo4-AM fluorescence signal intensity in response to 75mM KCl in Q5 (Ctrl) and Q6 (22q11.2) hiPSC-derived neurons at DIV37 (KS D=0.4865, P=0.003). (B) Quantification of KCl-induced Fluo4 intensity peak amplitude (ΔF) shows a reduction in Q6 line (P<0.0001). Q5 (Ctrl) n=21, Q6 (22q11.2) n=24 neuronal cells. Data are presented as mean ±SEM, unpaired two-tailed t-test or Kolmogorov–Smirnov test as indicated, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

Fig. S8: PPI network analysis of the 103 shared DEGs normalized in both Q6/EMC10^{HET} and Q6/EMC10^{HOM} NGN2-iNs. (**A**) Constructed directional PPI network out of the 30 matched candidates shown in red (PPI network; number of nodes: 150, number of edges: 365, average degree: 4.867, cluster of coefficient: 0.065). (**B**) GO term biological process: Enrichment analysis of matched proteins network.

Fig. S9: Social Memory is impaired in juvenile *Df(16)A*$^{+/-}$ mice. (A) Three-week-old juvenile *Df(16)A*$^{+/-}$ mice show a robust SM deficit compared to WT mice as indicated by the significant difference in trial 2 interaction time upon reintroduction of a familiar juvenile mouse [two-way ANOVA for Trial X Genotype Interaction matching by trial: F (1, 52) = 28.76 P<0.0001; post hoc Tukey, P= 0.0002]. **(B)** A negative difference score (trial 1- trial 2) confirms the SM deficit in juvenile *Df(16)A*$^{+/-}$ mice compared to WT littermates [unpaired two-tailed t-test]. WT mice pairs: n=19 (8 males, 11 females), *Df(16)A*$^{+/-}$ mice pairs: n=9 (7 males, 2 females). Data are presented as mean ± SEM, ***P < 0.001; ****P<0.0001.

Fig. S10. Genetic restoration of Emc10 levels in adulthood rescues SM performance in *Df(16)A*$^{+/-}$ mice. **(A)** *Emc10* 'knockout-first' conditional allele. The 'knockout-first' allele (tm1a) contains an IRES:lacZ trapping cassette and a floxed promoter-driven neo cassette inserted into the intron of Emc10 gene, disrupting gene function. Flp converts the 'knockout-first' allele to a

conditional allele (tm1c), restoring gene activity. Cre deletes the promoter-driven selection cassette and floxed exon of the tm1a allele to generate a lacZ-tagged allele (tm1b) or deletes the floxed exon of the tm1c allele to generate a frameshift mutation (tm1d), triggering NMD of the deleted transcript. **(B)** *E*xpression levels of *Emc10-1 mRNA* transcript in PFC of *Emc10*$^{tm1c+/-}$*; UBC-cre/ERT2; Df(16)A*$^{+/+}$ and *Emc10*$^{tm1c+/-}$*; UBC-cre/ERT2; Df(16)A*$^{+/-}$ mice [referred to as WT and *Df(16)A*$^{+/-}$] following adult TAM treatment. qRT-PCR analysis shows TAM- mediated normalization of *Emc10-1* mRNA levels in the PFC of *Df(16)*$^{+/-}$ mice. Significant upregulation of *Emc10-1* mRNA expression level seen in corn oil-treated *Df(16)A*$^{+/-}$ compared to corn oil-treated WT mice [one-way ANOVA, F(3, 12)=22.58, P<0.0001; post hoc Tukey, P=0.0013]. Following TAM treatment, *Emc10-1* expression is normalized to near WT levels in TAM-treated *Df(16)A*$^{+/-}$ compared to corn oil-treated *Df(16)A*$^{+/-}$ mice (post hoc Tukey, P=0.0098). *Emc10-1* reduction is also observed in TAM-treated WT compared to corn oil-treated WT mice (post hoc Tukey, P=0.0131). Corn oil-treated WT mice: n=5, corn oil-treated *Df(16)A*$^{+/-}$ mice: n=3, TAM-treated WT mice: n=4, and TAM-treated *Df(16)A*$^{+/-}$ mice: n=4. **(C)** Emc10 protein levels in PFC of WT and *Df(16)A*$^{+/-}$ mice following adult TAM treatment. Left panel: Emc10 protein levels are significantly elevated in corn oil-treated *Df(16)A*$^{+-}$ compared to corn oil-treated WT mice [one-way ANOVA, F(2, 7)=6.216 , P=0.0281, post hoc Tukey, P=0.0300]. Emc10 protein level is reduced in TAM-treated *Df(16)A*$^{+/-}$ compared to corn oil-treated *Df(16)A*$^{+/-}$ mice (post hoc Tukey, P=0.0634). Corn oil-treated WT mice: n=4, corn oil-treated *Df(16)A*$^{+/-}$ mice: n=3, TAM-treated *Df(16)A*$^{+/-}$ mice: n=3. Right panel: Representative Western Blot. Tubulin was used as loading control. **(D-E)** *Emc10* mRNA expression levels of both *Emc10* isoforms: *Emc10-1* **(D)** and *Emc10-2* **(E)**, with or without a TMD respectively (*7*), as assayed by qRT-PCRs in the HPC of the *Emc10*$^{tm1c+/-}$*; UBC-cre/ERT2; Df(16)A*$^{+/+}$ and *Emc10*$^{tm1c+/-}$*; UBC-cre/ERT2; Df(16)A*$^{+/-}$ mice [referred to as WT and *Df(16)A*$^{+/-}$] following adult TAM treatment. **(D)** qRT-PCR analysis shows TAM-mediated restoration of *Emc10-1* mRNA levels in the HPC of *Df(16)A*$^{+/-}$ mice. Significant upregulation of *Emc10-1* mRNA expression level seen in corn oil-treated *Df(16)A*$^{+/-}$ compared to corn oil-treated WT mice [one-

way ANOVA, F(3, 11)=16.77, P<0.001; post hoc Tukey, P=0.0027]. Following TAM treatment, *Emc10-1* expression is restored to near WT levels in *Df(16)A*$^{+/-}$ compared to corn oil-treated *Df(16)A*$^{+/-}$ mice (post hoc Tukey, P=0.0132). *Emc10-1* reduction is also observed in TAM-treated WT compared to corn oil-treated WT mice (post hoc Tukey, P=0.0485). **(E)** qRT-PCR analysis shows TAM-mediated restoration of *Emc10-2* mRNA levels in the HPC of *Df(16)A*$^{+/-}$ mice. Significant upregulation of *Emc10-2* mRNA expression level seen in corn oil-treated *Df(16)A*$^{+/-}$ compared to corn oil-treated WT mice [one-way ANOVA, F(3, 11)=28.28, P<0.0001; post hoc Tukey, P=0.0284]. Following TAM treatment, *Emc10-2* expression is restored to near WT levels in *Df(16)A*$^{+/-}$ compared to corn oil-treated *Df(16)A*$^{+/-}$ mice (post hoc Tukey, P=0.0002). *Emc10-2* reduction is also observed in TAM-treated WT compared to corn oil-treated WT mice (post hoc Tukey, P=0.0005). Corn oil-treated WT mice: n=5, corn oil-treated *Df(16)A*$^{+/-}$ mice: n=3, TAM-treated WT mice: n=3, and TAM-treated *Df(16)A*$^{+/-}$ mice: n=4. **(F)** Expression levels of *Emc10-1 mRNA* transcript in cerebellum (CB) of WT and *Df(16)A*$^{+/-}$ mice following adult TAM treatment. qRT-PCR analysis shows TAM mediated normalization of *Emc10-1* mRNA levels in the PFC of *Df(16)A*$^{+/-}$ mice. Significant upregulation of *Emc10-1* mRNA expression level seen in corn oil-treated *Df(16)A*$^{+/-}$ compared to corn oil-treated WT mice [one-way ANOVA, F(3, 10)=37.43, P<0.0001; post hoc Tukey, P<0.0001]. Following TAM treatment, *Emc10-1* expression is normalized to WT levels in TAM-treated *Df(16)A*$^{+/-}$ compared to corn oil-treated *Df(16)A*$^{+/-}$ mice (post hoc Tukey, P=0.0003). *Emc10-1* downregulation is also observed in TAM-treated WT compared to corn-oil-treated WT mice (post hoc Tukey, P=0.0122). Corn oil-treated WT mice: n=5, corn oil-treated *Df(16)A*$^{+/-}$ mice: n=2, TAM-treated WT mice: n=3, and TAM-treated *Df(16)A*$^{+/-}$ mice: n=4. **(G)** Corn oil-treated *Df(16)A*$^{+/-}$ mice show a robust SM deficit compared to corn oil-treated WT mice as indicated by the significant difference in trial 2 interaction time upon reintroduction of a familiar juvenile mouse [three-way ANOVA for Trial X Genotype X Treatment Interaction matching by trial: F (1, 35) = 8.823 P=0.0053; post hoc Tukey, P= 0.0047]. A reduction in trial 2 interaction time indicates rescue of the SM deficit in TAM-treated *Df(16)A*$^{+/-}$ compared to

corn oil-treated *Df(16)A*$^{+/-}$ mice (post hoc Tukey, P= 0.0082). **(H)** A negative difference score (trial 1- trial 2) confirms the SM deficit in corn oil-treated adult *Df(16)A*$^{+/-}$ mice compared to WT littermates [two-way ANOVA for Genotype X Treatment interaction: F (1, 35) =8.823, P=0.0053; post hoc Tukey, P= 0.0048]. Increase in the difference score of *Df(16)A*$^{+/-}$ mice in TAM- vs corn oil- treated group demonstrates rescue of SM performance (post hoc Tukey, P= 0.0181). Corn oil-treated WT mice: n=12 (7 males, 5 females), corn oil-treated *Df(16)A*$^{+/-}$ mice: n=7 (3 males, 4 females), TAM-treated WT mice: n=11 (6 males, 5 females), and TAM-treated *Df(16)A*$^{+/-}$ mice: n=9 (4 males, 5 females). **(I)** Tamoxifen (TAM) mediated Emc10 down-regulation does not rescue hyperactivity in *Df(16)A*$^{+/-}$ mice in the open field (OF) assay as demonstrated in the total distance traveled. In a 1-h exposure to a novel OF arena *Df(16)A*$^{+/-}$+ TAM mice compared with WT + TAM mice remain as hyperactive [one-way ANOVA, F(3, 31)= 8.052, P=0.0004; post hoc Tukey, P= 0.0222] as *Df(16)A*$^{+/-}$ + oil mice compared with WT + oil mice [one-way ANOVA, F(3, 31)= 8.052, P=0.0004; post hoc Tukey, P= 0.0047]. Corn-oil treated WT mice: n= 10, TAM-treated WT mice: n= 9, corn-oil treated *Df(16)A*$^{+/-}$ mice: n= 10, TAM-treated *Df(16)A*$^{+/-}$mice: n= 6. Data are presented as mean ± SEM, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

Fig. S11: In vitro and in vivo screening of designed ASOs. (A) *Emc10* mRNA levels in 4T1 cells following 7μM treatment with *Emc10* ASOs, data normalized to untransfected controls (UTC), and lead *Emc10*^{ASO1} noted in red. **(B)** Dose dependent reductions in *Emc10* mRNA levels in 4T1 cells following treatment with lead *Emc10*^{ASO1}, but not with a negative control^{ASO1}. Data expressed at % UTC. **(C)** qRT-PCR analysis shows bilateral reduction of *Emc10* mRNA expression levels in *Emc10*^{ASO1} compared to the Ctrl^{ASO1} treated WT mice in the left (unpaired two-tailed t-test, P= 0.0285; Ctrl^{ASO1} treated-WT male mice: n=8, *Emc10*^{ASO1} treated-WT male mice: n=8) and the right HPC (unpaired two tailed t-test, P= 0.0087; Ctrl^{ASO1} treated-WT mice: n=7, and *Emc10*^{ASO1} treated-WT mice: n=8). **(D)** Western blot analysis shows bilateral reduction of Emc10 protein expression in the left (P= 0.0321; unpaired two-tailed t-test; Ctrl^{ASO1} treated- WT

male mice: n=3, *Emc10*^{ASO1} treated-WT male mice: n=4) and right HPC (P= 0.0448; unpaired two-tailed t-test; Ctrl^{ASO1} treated-WT male mice: n=3, *Emc10*^{ASO1} treated-WT male mice: n=3). **(E)** mRNA expression analysis of astroglial (*Gfap*, left panel; P= 0.177; one-way ANOVA) and microglial (*Aif1*, right panel; P= 0.1527; one-way ANOVA) activation revealed no significant differences across groups. Untreated male mice; n=4, Ctrl^{ASO1} treated-WT male mice: n=4, *Emc10*^{ASO1} treated-WT male mice: n=4.

Fig. S12: Social memory interaction task with novel stimulus mice. (A-B) Control experiment for direct interaction test using two different novel mice in trials 1 and 2. **(A)** No significant difference in SM trials is observed across groups upon reintroduction of a novel juvenile mouse indicating SM rescue is not due to task fatigue [three-way ANOVA for Trial X Genotype X Treatment matching by trial; F (1, 30) = 0.3001, P=0.5878]. **(B)** No significant changes across groups in SM difference score upon reintroduction of a novel juvenile mouse [two-way ANOVA for Genotype X Treatment interaction; F(1, 30)=0.3001 P=0.5878]. Ctrl^{ASO}-treated WT: n=8 (4 males, 4 females), Emc10^{ASO} treated WT: n= 10 (4 males, 6 females), n=8 Ctrl^{ASO}-treated *Df(16)A*$^{+/}$ (3 males, 5 females) and Emc10^{ASO}-treated *Df(16)A*$^{+/}$: n=8 (4 males, 4 females). Data are presented as mean ± SEM, *P < 0.05; ***P < 0.001.

Fig. S13: In vivo post-injection screening of designed ASOs. (A-C) *In vivo* efficacy of selected ASOs in suppressing the levels of *Emc10* mRNA in the cortex of WT mice at 2- and 8-weeks post injection. Three ASOs were selected from an initial screen for the analysis shown here, based on their pharmacological efficacy. 700 ug of ASOs were injected into the right lateral ventricle of C57Bl/6 mice. Depicted is their efficacy in suppressing the levels of *Emc10* mRNA in the **(A)** retrosplenial cortex (cortex) and **(B)** thoracic spinal cord (TSC) at both 2- and 8-wks following a single bolus dose. **(C)** Calculation of the approximate time to normal expression (~T100%) from

the 2- and 8-week *Emc10* expression data. ~T100% for Emc10 #1466182 ASO is 26 weeks but this remains to be empirically determined.

Fig. S14: Emc10^{ASO2} reduces Emc10 expression in adult *Df(16)A*$^{+/-}$ mice.(A) Mouse brains collected three weeks post ICV injection were stained with an ASO antibody (green) and counterstained with neuronal marker NeuN (red) and nuclear stain Hoechst (blue). A robust and uniform ASO2 diffusion is observed in the HPC (top panel) and PFC (middle panel). Overlap with NeuN confirms its presence in neuronal cells. Accumulation in glial cells, specifically GFAP labeled astrocytes is also observed. Images are taken with 10x and 20x objectives. **(B-C)** Y-maze task in adult male mice. **(B)** Locomotor activity is unchanged between WT and *Df(16)A*$^{+/}$ mice (P=0.8844) reflected by the number of total arm entries in the Y-maze task. WT mice: n=12, *Df(16)A*$^{+/}$ mice: n=11. **(C)** No significant changes in the number of total arm entries between the groups after 3-weeks of ASO-injection, indicating normal locomotor activity in this task. Ctrl^{ASO}-treated male WT mice: n=8, Emc10^{ASO} treated male WT mice: n=8, Ctrl^{ASO}-treated male *Df(16)A*$^{+/}$ mice: n=8 and Emc10^{ASO}-treated male *Df(16)A*$^{+/}$ mice: n=5). **(D-F)** ASO-mediated inhibition of *Emc10* in different brain regions of *Df(16)A*$^{+/-}$ mice used in the Y-maze assay after 3-weeks of injection. **(D)** qRT-PCR analysis shows significant upregulation of *Emc10* mRNA expression levels in the HPC of Ctrl^{ASO} treated-*Df(16)A*$^{+/-}$ compared to WT mice [one-way ANOVA, F (3, 25)=50.42, P<0.0001; post hoc Tukey, P= 0.0009]. Following ASO treatment, *Emc10* expression is normalized to WT levels in Emc10^{ASO} treated-*Df(16)A*$^{+/–}$ compared to Ctrl^{ASO} treated-*Df(16)A*$^{+/-}$ mice (post hoc Tukey, P= <0.0001). **(E)** qRT-PCR analysis shows a significant up-regulation of *Emc10* mRNA expression levels in the PFC of Ctrl^{ASO} treated-*Df(16)A*$^{+/-}$ compared to WT mice [one-way ANOVA, F (3, 25)=14.45 , P=<0.0001; post hoc Tukey, P=0.0097]. Following ASO treatment, *Emc10* expression is normalized to WT levels in the Emc10^{ASO} treated-*Df(16)A*$^{+/–}$ compared to Ctrl^{ASO} treated-*Df(16)A*$^{+/-}$ mice (post hoc Tukey, P=0.0258). **(F)** qRT-PCR analysis shows a significant up-regulation of *Emc10* mRNA expression levels in Somatosensory Cortex

(SSC) of Ctrl^{ASO} treated-*Df(16)A*$^{+/-}$ compared to WT mice [one-way ANOVA, F (3, 25) =17.91, P=<0.0001; post hoc Tukey, P<0.0004]. Following ASO treatment, *Emc10* expression is normalized to WT levels in Emc10^{ASO} treated-*Df(16)A*$^{+/-}$ compared to Ctrl^{ASO} treated-*Df(16)A*$^{+/-}$ mice (post hoc Tukey, P=<0.0001). Ctrl^{ASO}-treated WT male mice: n=8, Ctrl^{ASO}-treated *Df(16)A*$^{+/}$ male mice: n=8, Emc10^{ASO}-treated WT male mice: n=5 and Emc10^{ASO}-treated *Df(16)A*$^{+/}$ male mice: n=5. **(G-H)** Y-maze task in adult male mice: No significant changes were observed in the total number of arm entries between groups, indicating normal locomotor activity in this task at both 4 weeks **(G)** and 9 weeks **(H)** following ASO injection. Ctrl^{ASO}-treated WT: n=9, Emc10^{ASO} treated WT mice: n=8, Ctrl^{ASO}-treated *Df(16)A*$^{+/}$ mice: n=8 and Emc10^{ASO}-treated *Df(16)A*$^{+/}$ mice: n=8. Unpaired students t-test or one-way ANOVA as indicated. Data are presented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.01, ****P<0.0001.

Supplementary Tables

Table S1: Clinical and demographic characteristics of 22q11.2DS/SCZ patients and healthy controls.

Table S2: Differentially expressed microRNAs in cortical neurons (DIV8) from 22q11.2DS/SCZ (Q6) and control line (Q5) derived using small-molecule inhibitors of SMAD and WNT signaling pathways.

Table S3: DEGs in cortical neurons (DIV8) from 22q11.2DS/SCZ (Q6) and control line (Q5) derived using small-molecule inhibitors of SMAD and WNT signaling pathways.

Table S4: List of targets of downregulated miRNAs identified from the intersection of predicted targets of downregulated miRNAs and up-regulated DEGs in hiPSC-derived cortical neurons at DIV8.

Table S5: Predicted targets of miR-185-5p, miR-1286 and miR-1306-5p in *EMC10* 3'UTR.

Table S6: DEGs in NGN2-iNs (DIV21) from 22q11.2DS/SCZ (Q6) and control line (Q5) that were normalized ('rescued') in Q6 EM10 HET and Q6 EMC10 HOM lines.

Table S7: List of 103 DEGs normalized in both Q6 EMC10 HET and EMC10 HOM lines, used for PPI konnect2prot network analysis.

Table S8: List of genes upregulated in $Ctrl^{ASO1}$ treated-*Df(16)A*$^{+/-}$ mice compared to $Ctrl^{ASO1}$ treated-WT mice but not in the $Emc10^{ASO1}$ treated-*Df(16)A*$^{+/-}$ compared to $Emc10^{-ASO1}$ treated-WT mice.

Table S9: List of primer sequences used for qRT-PCRs.

Supplemental Materials and Methods

Mice: Mice of both sexes and genotypes (mutant and WT littermates) were used for behavioral testing. Separate cohorts of mice were used for Social Memory and Fear Conditioning assays. In general, mice were group housed under a 12-h light/12-h dark cycle with controlled room temperature and humidity. Food and water were provided *ad libitum*. All behavioral experiments were performed on adult male and female mice during the light cycle. All animal procedures were carried out in accordance with and approved by the Columbia University Institutional Animal Care and Use Committee.

Cell line donors

Q6 and Q5 lines: The Q6 line donor is a 20-year-old female patient with a history of developmental delay and an overall Full-Scale IQ in the low 80s. She was clinically diagnosed with 22q11.2DS by FISH testing. Her psychotic symptoms, including disorganized behavior and command auditory hallucinations, started when she was 17 years old. During the first break episode, due to the severity of her psychotic symptoms, the patient was hospitalized and was diagnosed with schizophrenia. The patient also developed depressive symptoms, including frequent suicidal ideation. One year after her schizophrenia diagnosis, in addition to her severe psychotic symptoms, the patient was also diagnosed to be in a catatonic state. The patient has remained severely psychotic since the onset of these symptoms at age 17 and has been on multiple antipsychotics without experiencing any clinically meaningful benefit. Regarding her treatment history includes various first-line antipsychotics (including olanzapine, stelazine, aripiprazole, haloperidol, risperidone and clozapine); several antidepressants (sertraline and fluoxetine); a mood stabilizer (lithium) and benzodiazepines (e.g., lorazepam). None of these medications reportedly led to any clinically significant improvement in either the psychotic or the depressive symptoms. The patient has also undergone 2 rounds of electroconvulsive treatment (ECT), but with only short-lived improvement. The Q5 line donor is the probands dizygotic twin sister who

does not carry a 22q11.2 deletion and her psychiatric evaluation ruled out any history of psychiatric symptoms (**Supplementary Table S1**). Sibling are of Caucasian Western European descent.

Q1 and Q2 lines: The Q1 and Q2 line were previously described (as DEL3 and WT3) (*68*). The Q1 line donor is a 32-year-old male patient with a history of developmental and speech delay. He was clinically diagnosed with 22q11.2DS by FISH testing at age 4. His psychotic symptoms, started when he was 12 years old. The patient was hospitalized once at age 10 before he was formally diagnosed with schizophrenia. During that time, he also experienced one seizure. The patient also developed mood lability and has OCD-like symptoms although does not meet full criteria for DSM-IV/V OCD. Regarding his treatment history, it includes various first-line antipsychotics as well as metyrosine (started when he was 15). The Q2 line donor is the proband's brother, who does not carry a 22q11.2 deletion and his psychiatric evaluation ruled out any history of psychiatric symptoms (**Supplementary Table S1**). Siblings are of Caucasian Western European descent.

QR20 and QR27 lines: QR20 (MH0159020) and QR27 (MH0159027) lines were obtained from the NIMH Repository and Genomics Resource (http://www.nimhstemcells.org/) (*69*). The donor of the QR27 line, 31-year-old male was diagnosed with schizoaffective disorder and 22q11.2DS (*69*) while the donor of the QR20 line (58 year old male) was free from any psychiatric symptoms (**Supplementary Table S1**). Both are of Caucasian descent.

hiPSC generation and characterization. Q5 and Q6 hiPSC lines were generated at the Columbia Stem Cell Core via non-integrating Sendai virus-based reprogramming (*70*) of monocytes from a donor with 22q11.2DS and SCZ and a healthy sibling control. The Q1 and Q2 lines were generated at the Columbia Stem Cell Core and characterized as described earlier (*68*). QR20 and QR27 lines were obtained from the NIMH Repository and Genomics Resource (http://www.nimhstemcells.org/) (*69*). Karyotyping was performed on twenty G-banded

metaphase cells at 450–500 band resolution as previously described (*71*) to ensure the absence of chromosomal abnormalities in all patient and control derived cell lines (**Fig. S1A, Fig. S6B**). We confirmed the genotypes of Q6 patient- and Q5 control-derived hiPSCs using a Multiplex Ligation-dependent Probe Amplification (MLPA) assay to detect copy number changes (**Fig. S1B, C**). To confirm stemness of hiPSC lines, we performed qRT-PCR for markers *NANOG* and *OCT4/POU5F1* (**Fig. S1D**).

Genome editing of Q6(22q11.2) hiPCS line. The genomic gRNA target sequences were EMC10-g1: ACAGTGCCAACTTCCGGAAG (PAM suffix: CGG) and EMC10-g2: GGGACAAGGTACCATCCTGC (PAM suffix: TGG). Mutations in *EMC10* were confirmed by NGS and no off-target candidates were predicted in both lines using COSMID tool (https://crispr.bme.gatech.edu) (*72*). Karyotyping confirmed normal chromosome complement in both modified lines (**Fig. S6B**). qRT-PCR and WB assays were performed in both lines for the hiPSC markers *NANOG* and *OCT4/POU5F1* to confirm stemness as well as the RNABP1 gene located within 22q11.2 locus to confirm the deletion (**Fig. S6C-E**). qRT-PCR and western blot assays were performed to confirm reduction or elimination of EMC10 levels in the *EMC10* LoF mutant lines (**Fig. S6F-G**).

Culture and neuronal induction of hiPSC lines: hiPSC lines were maintained in mTeSR Plus medium (catalog#05825, Stemcell Technologies, Vancouver, Canada) on Matrigel (catalog#354277, Corning, Corning, NY, USA) coated tissue culture plate. Cells were fed on any other day and passaged weekly using RelesR (catalog#05872, Stemcell Technologies, Vancouver, Canada) dissociation reagent in accordance to their manual. Disassociated cells were pre-plated as reported earlier(*20*) at a density of 200,000 cells/cm^2 supplemented with 10 μM Y-27632 (catalog# 1254, Tocris Bioscience, Bristol, United Kingdom) on Matrigel-coated plates and differentiation started when confluent. Differentiation of hiPSC was performed as indicated below:

(i) hiPSC differentiation into cortical neurons, via a combination of small molecule inhibitors, was performed as described with few modifications (*20*). In brief, inhibitors used in LSB+X/P/S/D induction included LDN193189 (250 nM; catalog#04-0074, Stemgent, REPROCELL USA Inc., Beltsville, MD, USA), SB431542 (10 μM; catalog#1614, Tocris Bioscience, Bristol, United Kingdom), XAV939 (5 μM; catalog#3748, Tocris Bioscience, Bristol, United Kingdom), PD0325901 (1 μM; catalog#4192, Tocris Bioscience, Bristol, United Kingdom), SU5402 (5 μM; catalog#1645-05, BioVision Inc., Milpitas, CA, USA), DAPT (10 μM; catalog#2634, Tocris Bioscience, Bristol, United Kingdom). Until day 4 of differentiation, TeSR E6 medium (catalog#05946, Stemcell Technologies, Vancouver, Canada) was added in 1/3 increments every other day. Then, neurobasal (NB) plus medium supplemented with N2 (catalog#17502-048, Gibco, Life Technologies, Grand Island, NY, USA) and B27 plus supplement (catalog#A35828-01, Gibco, Life Technologies, Grand Island, NY, USA) was added in 1/3 increments every other day from day 4, until reaching 100% neurobasal plus/B27 plus L-glutamine (catalog#35050-061, Gibco, Life Technologies, Grand Island, NY, USA) containing medium supplemented with BDNF (20 ng/ml; catalog#248-BDB, R&D Systems, Minneapolis, MN, USA), cAMP (0.5 mM; catalog#A92902, Sigma-Aldrich, St. Louis, MO, USA) and ascorbic acid (0.2 mM; Sigma-Aldrich, St. Louis, MO, USA) (BCA) at day 8 as described (20). For long-term culture, cells were passaged on day 8 of differentiation by Accutase (catalog#AT-104, Innovative Cell Technologies Inc., San Diego, CA, USA) dissociation for 6 min at 37 °C. Cells were replated at 200,000 cells/cm^2 onto Matrigel coated culture dishes. NB plus/B27 plus and BCA medium were used for passaging and long-term culture. Culture medium was changed every 3–4 days.

(ii) hiPSC differentiation into neurons via NGN2 overexpression was performed as described previously with few modifications (*31-33*). In brief, differentiation of hiPSC into neurons (iNs) was conducted by using the lentiviral infection of NGN2 and the reverse tetracycline transactivator rtTa into hiPSCs, followed by selection on puromycin. The lentiviral particles were commercially produced by VectorBuilder (Chicago, IL, USA) using the established and published plasmids

pLenti-FUW-M2rtTA (FUW-M2rtTA deposited by Rudolf Jaenisch, Addgene plasmid #20342; http://n2t.net/addgene:20342; RRID:Addgene_20342, (*73*)), pLenti-TetO-hNGN2-eGFP-puro (pLV-TetO-hNGN2-eGFP-Puro deposited by Kristen Brennand, Addgene, plasmid#79823; http://n2t.net/addgene:79823; RRID:Addgene_79823, (*33*)) and for calcium imaging, the pLenti-TetO-hNGN2-puro (pLV-TetO-hNGN2-Neo deposited by Kristen Brennand, Addgene plasmid # 99378; http://n2t.net/addgene:99378; RRID:Addgene_99378,(*74*)). Around 200k cells per well (24-well format) were plated on Matrigel coated wells/coverslips in mTeSR plus media supplemented with 10 μM Y-27632. On day 0, lentiviruses were added in fresh basic media, containing always DMEM/F12 (catalog#11330032, Thermo Fisher Scientific, Waltham, MA, USA), human BDNF (10 ng/ml), human NT-3 (10 ng/ml, catalog#450-03, PeproTech, East Windsor, NJ, USA), mouse laminin (0.1 μg/ml, catalog#354232, Corning, NY, USA), N2 supplement, B27 plus supplement, non-essential amino acids (NEAA, catalog#SH30238.01, Cytiva, Marlborough, MA, USA) supplement and doxycycline (1 mg/ml, catalog#D9891-1G, Sigma-Aldrich, St. Louis, MO, USA) to induce TetO gene. On day 1, the culture medium was completely replaced with fresh basic media and a 48-hour puromycin selection (1 mg/l, catalog#P8833-10MG, Sigma-Aldrich, St. Louis, MO, USA) period was started. On day 3, for calcium imaging and morphology analysis, ca. 25% mouse glia cells (prepared as previously reported in (*33*)) were added to the basic media plus Ara-C (2μM, catalog#C1768-100M, Sigma-Aldrich, St. Louis, MO, USA) and 10% mouse astrocyte conditioned media (catalog#M1811-57, ScienCell, Carlsbad, CA, USA) to promote neuronal health and maturation. On day 5, total medium was changed with basic media plus Ara-C and 10% mouse astrocyte conditioned media. On day 7, total media was removed and replaced with BrainPhys Neuronal media with SM1 supplement (catalog#05792, STEMCELL Technologies, Vancouver, Canada) containing always human BDNF (10 ng/ml), human NT-3 (10 ng/ml), mouse laminin (0.1 μg/ml), N2 supplement, doxycycline (1 mg/ml) and 10% mouse astrocyte conditioned media. From day 9 on, half of the media were removed and replaced with supplemented BrainPhys media every other day. 2.5%

FBS (catalog#16141079, Thermo Fisher Scientific, Waltham, MA, USA) was added to the culture medium on day 11 to those cells which were co-cultured with astrocytes to support astrocyte viability. iN cells were assayed for experiments as indicated.

Cell culture transfection: Transfection of cortical neurons at day 8 of differentiation were performed with the transfection reagent Lipofectamine 2000 (#11668-030, Life Technologies, Carlsbad, CA, USA) as described earlier (*26*)). Cells were transfected for 48 hours with 25 pmol per well (24-well format) of miRNA mimic Pre-miR miRNA precursors (Ambion, Thermo Fisher Scientific, Waltham, MA, USA) as indicated: pre-miR Negative Control #1 (catalog#17110), hsa-miR-185-5p (catalog#17100, PM12486) and hsa-miR-485-5p (catalog#17100, PM10837) or with 50 pmol per well (24-well format) of miRNA miRVana inhibitors (Ambion, Thermo Fisher Scientific, Waltham, MA, USA) as indicated: miRNA inhibitor Neg. Ctrl #1 (catalog#4464076), hsa-miR-185-5p inhibitor (catalog#4464084, MH12485), hsa-miR-485-5p inhibitor (catalog#4464084, MH10837).

TAM preparation and feeding: We used oral gavage for TAM delivery during postnatal day 56-70. A TAM feeding protocol were used as previously described (*64*). In brief, TAM (catalog#T5648, Sigma-Aldrich, St. Louis, MO, USA) was dissolved in corn oil (catalog#C8267, Sigma-Aldrich, St. Louis, MO, USA) at 20mg/ml by vortexing. To avoid toxicity, the following dosages were used for adult animals (8-10 weeks): mice at 17–21 g body weight were fed 5 mg/day; mice at 22–25g body weight were fed 6mg/day; mice at 26–29g body weight were fed 7mg/day; mice at 30–35g body weight were fed 8mg/day. Adult animals were fed for 5 consecutive days followed by 2 days of rest. Animals were then fed for 5 more consecutive days followed by one week of rest before RNA/protein or SM assays were performed. Corn oil was used as vehicle control treatment.

ASOs: Mouse *Emc10*-targeting ASOs used in these studies were 20 bases in length, chimeric 2' -O- (2-methoxyethyl) (MOE)/DNA) oligonucleotides with phosphodiester and phosphorothioate linkages. The central gap of 10 deoxynucleotides is flanked on its 5' and 3' sides by five MOE modified nucleotides. Oligonucleotides were synthesized at Ionis Pharmaceuticals (Carlsbad, CA, USA) as described previously (*65, 66*). ASOs were solubilized in 0.9% sterile saline or PBS.

In vitro screening of ASOs: 4T1 cells were trypsinized, counted and diluted to 200,000 cells per ml in room temperature growth medium before adding 100 µL of the cell suspension to the wells of a 2 mm electroporation plate (Harvard Apparatus, Holliston, MA, USA) which contained 11 µL of 10X ASO in water. Cells were pulsed once at 130V for 6 mS with the ECM 830 instrument (Harvard Apparatus). After electroporation, the cells were transferred to a Corning Primeria 96 well culture plate (catalog #353872, Corning, NY, USA) containing 50 µL of growth medium. The cells were then incubated at 37° C and 5% CO2. After 24 hours, the cells were washed 1 x with PBS before lysing for RNA isolation and analysis. For each treatment condition duplicate wells were tested. ASO1081815 (TTGTTCCTACAGATCTAGGG, referred to in the manuscript as $Emc10^{ASO1}$) was used in behavioral and immunocytochemical assays.

In vivo screening of ASOs: Candidate *Emc10*-targeting ASOs (700ug) were stereotactically injected into the right lateral ventricle of C57Bl/6 mice (0.3 mm anterior, 1.0 mm dextrolateral, 3.0 mm ventral from bregma). Reduction of *Emc10* mRNA in the retrosplenial cortex and thoracic spinal cord was evaluate by qRT-PCR at 2 weeks following a single bolus dose. Three ASOs were selected from the screen based on their pharmacological efficacy: 1466167, 1466171 and 1466182. Animals were injected with these ASOs in the right lateral ventricle as described above (n= 4) and euthanized 8 weeks post injection. Animals were evaluated with an observational functional battery test at 3 hours after dosing and then every two weeks until euthanasia. The retrosplenial cortex and thoracic spinal cord were harvested for qRT-PCR analysis of *Emc10*, *Aif1*

(microglia marker), *Cd68* (phagocytic microglia marker) and *Gfap* (reactive astrocyte marker) mRNA. Brain and spinal cord were also harvested and fixed in formalin solution for histological evaluation. Tissues were stained for H&E and IBA1 (microglia marker), CD68 (phagocytic microglia marker) GFAP (reactive astrocyte marker) and Calbindin (Purkinje Cell marker). Bolus injections of all three candidate ASOs resulted in similar reductions of the *Emc10* mRNA at both 2 and 8 weeks. Of the three candidate ASOs, ASO1466182 (GCCATATCTTTATTAATTAC, referred to in the manuscript as $Emc10^{ASO2}$) showed no signs of in life toxicity and the tolerability marker gene expression was similar between ASO- and vehicle-treated animals in the tissues evaluated. There was no positive IBA1 IHC staining in the CNS of any of the treated animals. Therefore, it was ranked as the best candidate for further behavioral analysis in mutant mice.

Stereotactic Intracerebroventricular (ICV) Injections of ASOs: The syringe was attached to a glass pipette with a long-tapered end made using a Sutter pipette puller model P-87. Anesthesia was delivered using Kent Scientific VetFlo Traditional Vaporizer VetFlo-1205S (Kent Scientific Corporation, Torrington, CT, USA). Mice were initially put in the isoflurane chamber using 3% isoflurane mixture for 5 minutes, which was lowered to 2-2.5% when fixed to the stereotactic station. We used KOPF Small Animal Stereotaxic Instruments (Model 940). Carprofen (5 mg/kg, Zoetis Inc., Kalamazoo, MI, USA), and Bupivacaine (2 mg/kg, Hospira, Inc., Lake Forest, Il, USA) were delivered subcutaneously before the incision was made. Additionally, Dexamethasone (2 mg/kg, Bimeda-MTC Animal Healt Inc., Cambridge, ON, Canada) was delivered intramuscularly. The surgical site was shaved and sterilized with betadine and 70% ethanol three times. A small midline incision was made and a hole was drilled in the skull. Stereotactic bregma coordinates used for the right ventricle were - 0.5 mm posterior, -1.1 lateral, and -2.8 mm dorsoventral. Mice were injected with 4 ul of either the $Ctrl^{ASO1/ASO2}$ or $Emc10^{ASO1/ASO2}$ ($Emc10^{ASO1}$: 292 ug, $Emc10^{ASO2}$: 280 ug) at a rate of 0.5ul/minute. The needle was left in the injection site for 10 minutes to allow diffusion and avoid back flow of the ASO upon retraction of the glass pipette.

Mice were maintained at a temperature of 37°C for the duration of the surgery using a water regulated heating pad (T/Pump TP 700, Stryker Corporation, Kalamazoo, MI, USA). Mice were placed on heating pads for in cage recovery and Carprofen was administered subcutaneously for three days post-surgery. Mice were then subjected to behavioral experiments/immunohistochemistry three weeks post-surgery. qRT-PCR assays were performed one week post behavioral assays.

Quantitative Real Time PCR (qRT-PCR): Total RNA was extracted from HPC, PFC and Somatosensory Cortex (SSC) using the RNeasy Mini Kit (catalog#1038703, Qiagen, Hilden, Germany) or using the miRVana miRNA isolation kit (#AM1560, Ambion, Thermo Fisher Scientific, Waltham, MA, USA) for RNA extraction of hiPSC and derived neurons samples in accordance to their manuals. cDNA was synthesized using High-Capacity RNA-to-cDNA Kit from Applied Biosystems (cat#4387406, Thermo Fisher Scientific Baltics, Vilnius, Lithuania). qRT-PCR was performed using the Bio-Rad CFX-384 qPCR instrument (Bio-Rad, Hercules, CA, USA) using TaqMan Universal Master Mix II, with UNG (catalog#4440038, Thermo Fisher Scientific Baltics, Vilnius, Lithuania). Mouse *Gapdh* Endogenous Control (cat# 4352339E, Life Technologies, Warrington, United Kingdom) served as housekeeping gene and TaqMan Mm01197551_m1 (catalog#4351372) probe for mouse *Emc10* as well as Mm01208065_m1 for *Emc10-1* (cat# 4351372) and Mm01197555_m1 for *Emc10-2* (cat# 4351372) mRNA detection were used for the qRT-PCR assay. For mouse qRT-PCR assay of Ctrl ASO^{ASO1}/$Emc10^{ASO1}$, threshold cycle of each sample was picked from the linear range to calculate the values for Starting Quantity (SQ) for all samples extrapolated using the Standard Curve. All samples were run together in triplicates on the same plate including the standard curve ran in duplicates. The SQ values were averaged over the triplicates. The values of *Emc10* mRNA levels were then normalized to the values from the *Gapdh* gene expression levels. For mouse qRT-PCR analysis of Ctrl ASO^{ASO2}/$Emc10^{ASO2}$, the average of triplicate CT values from each sample was used to calculate the relative RNA levels

($2^{-\Delta CT}$) as described earlier (*75*) and all values were then normalized to $Ctrl^{ASO2}$-treated WT group. qRT-PCR for hiPSC and derived neurons was performed using TaqMan or SYBR Green System (catalog#1725121, iTaq Universal SybrGreen Supermix with ROX; BIO-RAD, Hercules, CA, USA) for mRNA and/or pre-miRNA detection according to manufacturer's instructions. *U6* snRNA was used as housekeeping gene to normalize pre-miRNAs targets. For detection of *RANBP1* (catalog# 4331182, Hs01597912), *OCT4/POU5F1* (catalog#4331182, Hs04260367), *NANOG* (catalog#4331182, Hs02387400), *TBR1* (catalog#4331182, Hs00232429), *GFAP* (catalog#4331182, Hs00909233), *NEUROD1* (catalog#4331182, Hs00159598), *vGLUT1* (catalog#4331182, Hs00220404), *DLX1* (catalog#4331182, Hs00698288), BRN2 (catalog#4331182, Hs00271595) and *EMC10* (catalog#4331182, Hs00382250) mRNA TaqMan probes (Thermo Fisher Scientific, Waltham, MA, USA) were used, as indicated, with *GAPDH* as housekeeping gene control (human *GAPDH* endogenous control, catalog#4325792, Life Technologies, Warrington, United Kingdom). The average of triplicate CT values from each sample was used to calculate the relative RNA levels ($2^{-\Delta CT}$). Primer sequences for pre-miRNA are provided in the supplemental table (**Supplementary Table 9**). Primers were purchased from Integrated DNA Technologies (Coralville, IA, USA) and were diluted to a stock concentration of 100 μM.

Immunohistochemistry: Animals were euthanized using CO_2 and then perfused with 4% Paraformaldehyde. The brains were stored at 4°C in 4% PFA overnight and were then switched to 1x Phosphate Buffered Saline (PBS). 2.5% low melting agarose in 1xPBS buffer was added to the brains placed inside the plastic molds, which were then moved to 4°C to create a solid block for slicing. This block was then glued to the vibratome stage (Leica Vibratome VT10005, Wetzlar, Germany) and sectioned at 40 um thickness. Sections were rinsed in 1xPBS for 5 minutes and then blocked for 1 hour at room temperature in 2% Normal Goat Serum (NGS) and 0.3%Triton X-100 in 1xPBS solution. Sections were then incubated with either anti-ASO and NeuN or anti-ASO

and GFAP primary antibodies in blocking solution at 4°C and left on a shaker overnight. The following day, sections were washed three times with 1xPBS for 10 minutes and were then stained with Goat anti- rabbit along with either Goat anti-mouse or Goat anti-chicken secondary antibodies in 2% NGS and 0.4% Triton-X100 solution made in 1xPBS for two hours in the dark at room temperature (RT). Following two 10-minute washes with 1xPBS, sections were additionally stained with Hoechst nuclear stain diluted in 1xPBS for 15 minutes in the dark. Lastly, sections were washed three times with 1xPBS for 10 minutes. Sections from PBS solution were mounted on glass slides, air-dried and cover slipped in Prolong Diamond Antifade Mountant (catalog#P36970, Life Technologies Corporation, Eugene, OR, USA). Slides were left overnight in the dark and then stored at 4°C. Human neuronal cultures were fixed on coverslips in 4%PFA (catalog#22023, Biotium, Fremont, CA, USA) for 1h at RT and then blocked for 1.5h at RT in 0.1% Triton-X and 10% horse serum (catalog#H0146, Sigma-Aldrich, St. Louis, MO, USA) solution. After fixation, coverslips were stained with the primary antibody in a 0.1% Triton-X and 2% horse serum solution overnight at 4°C. Coverslips were then washed 3x 15 min with DPBS (catalog#D8537, Sigma-Aldrich, St. Louis, MO, USA) and cells were incubated for 1h with the secondary antibody at RT followed by 3x 15min DPBS washing. Tissue sections and cultured cells were imaged on W1-Yokogawa Spinning Disk Confocal (Nikon Instruments, Tokyo, Japan).

Antibodies for Immunohistochemistry: The following primary antibodies were used: Rabbit polyclonal anti-ASO antibody diluted 1:10000 (IONIS Pharmaceuticals, Carlsbad, CA, USA); Anti-GFAP antibody diluted 1:1000 (Aves Labs Inc., catalog#GFAP), Mouse monoclonal Anti-NeuN antibody diluted 1:200 (Millipore, catalog#MAB377), anti-TUJ1 1:500 (mouse monoclonal, catalog#T8660, Sigma-Aldrich, St. Louis, MO, USA), anti-TBR1 1:100 (rabbit monoclonal, #Ab183032, Abcam, Cambridge, MA, USA), anti-GFP 1:1000 (goat polyclonal, catalog#600-101-215, Rockland Immunochemicals, Pottstown, PA, USA), anti-MAP2 1:2000 (chicken polyclonal, catalog#5392, Abcam, Cambridge, MA, USA). The following secondary antibodies were used for

mouse at a dilution of 1:500: Goat anti-Rabbit (Alexa Floro 488: catalog#AA1008, Invitrogen, Waltham, MA, USA) against ASO; Goat anti-mouse (Alexa Floro 568: catalog#AA1004, Invitrogen, Waltham, MA, USA) against NeuN, and Goat anti chicken (Alexa Floro 568: catalog#A11041, Invitrogen, Waltham, MA, USA) against GFAP. Hoechst 33258 solution diluted 1:1000 (Catalog#94403, Sigma Aldrich, Saint Louis, MO, USA) was used for nuclear staining in brain slices and DAPI Fluoromount-G (catalog#0100-20, Southern Biotech, Birmingham, AL, USA) was used for cultured cells.

Analysis of dendritic complexity: Images of dendrites were acquired on a Nikon Spinning Disk Confocal Microscope and captured using the Nikon NIS Elements AR (v.5.21.03 64-bit) software. Images were acquired and analyzed as previously described (*7, 76*). Image analysis of dendritic complexity was conducted blind to genotype. Primary dendrites were defined as any branch emerging from the soma and a secondary dendrite as any branch emerging from a primary dendrite. Dendrite branches were semi-automatically traced using NeuronStudio software (v.0.9.92 64-bit) (*77*). The output .swc files were then processed in VAA3D (v.3.1.00) (*78-80*) and binary images were generated and analyzed using ImageJ (http://rsbweb.nih.gov/ij/, NIH, Bethesda, MD, USA).

Calcium imaging: Neuronal cells used in calcium imaging experiments were prepared on glass bottom dishes (14mm, catalog#P35G-1.5-14-C, MatTek, Ashland, MA, USA). Briefly, cells were incubated at DIV37-38 with 0.3μM Fluor4-AM (Invitrogen, catalog#F14201) for 30 min at 37 °C in incubation buffer medium (containing 170mM NaCl, 3.5mM KCl, 0.4mM KH_2PO_4, 20mM TES (N-tris[hydroxyl-methyl-2-aminoethane-sulfonic acid], 5mM $NaHCO_3$, 5mM glucose, 1.2mM Na_2SO_4, 1.2mM $MgCl_2$, 1.3mM CaCl2, pH 7.4) and washed once with incubation buffer medium before imaging. After imaging for 2'20” (baseline), 25mM KCl solution was added to the cells, followed by another 25mM KCl addition at 3’20” and 4’20” min. Live imaging was performed at room

temperature (~25 °C) on a W1-Yokogawa Spinning Disk Confocal (Nikon Instruments, Tokyo, Japan). ImageJ software with plugin for motion correction (MuliStackReg) and Excel were used to collect, manage and quantify time-lapse excitation ratio images by selecting cell body as ROI.

Protein extraction for Western blot: To extract proteins from mouse HPC, the tissue was dissected and homogenized in QIAzol lysis reagent (catalog#79306, Qiagen, Hilden, Germany). Chloroform was added to homogenate and the solution was then incubated at room temperature for 3 minutes. Tissue was spun at 12,000 x g at 4°C and the organic phase was collected for protein extraction. We followed an optimized protocol for protein extraction from Trizol solutions and used 5% SDS + 20mM EDTA + 140 mM NaCl buffer solution for protein pellet suspension (*81*). To extract proteins from mouse PFC, the tissue was dissected and homogenized using a modified Pierce RIPA lysis and extraction buffer (RIPA+) (catalog#89900, Thermo Scientific, Rockford, IL, USA) that contains a Halt Protease Inhibitor Cocktail (catalog#1861281, Thermo Scientific, Rockford, IL, USA). Cultured neurons cells were lysed at day 8 of differentiation. The cultured cells were once washed with cold DPBS (catalog#D8537, Sigma-Aldrich, St. Louis, MO, USA). Cells were then lysed by adding a modified Pierce RIPA lysis and extraction buffer (RIPA+). The plate was shaking for 20 min at 4°C on an orbital shaker (catalog#980173, Talboys, Troemner, Thorofare, NJ, USA). To remove cell debris, the lysates were centrifuged at maximum speed for 10 min at 4°C. The protein concentration of the supernatant for all protein samples was determined by Pierce BCA Protein Assay Kit (#23227, Thermo Scientific, Rockford, IL, USA).

Western Blots: For each lane, ~20 µg protein were run on a 4-12Bis-Tris Criterion XT Precast Gel (#3450123, Bio-Rad (Bio-Rad, Hercules, CA, USA) next to the Precision Plus Protein Dual Color Standard (catalog#161-0374, Bio-Rad, Hercules, CA, USA) in SDS-PAGE running buffer (catalog#1610788, Bio-Rad, Hercules, CA, USA) and afterwards transferred to a methanol-activated Immobilon-P PVDF (poly-vinylidene difluoride) membrane (catalog#IPCVH00010,

Merck Millipore Ltd., Carrigtwohill, Ireland) by tank blotting at 250mA for 90 min in a cold room (4°C) in blotting buffer (catalog#1610734, Bio-Rad, Hercules, CA, USA). The membrane was blocked for 2 h in TBS-T (tris buffered saline supplemented with 0.1 % Tween) containing 5 % milk powder. Antibody dilutions anti-*EMC10/Emc10* 1:1000 (rabbit polyclonal; catalog#Ab181209, Abcam, Cambridge, MA, USA), anti-DGCR8 1:1000 (rabbit monoclonal, catalog#Ab191875, Abcam, Cambridge, MA, USA), anti-RANBP1 1:500 (rabbit polyclonal, catalog#Ab97659, Abcam, Cambridge, MA, USA) and anti-alpha-Tubulin1:1000 (polyclonal rabbit; catalog#2144S, Cell Signal, Danvers, MA, USA) as loading control were prepared in TBS-T/milk and the membrane were incubated overnight at 4°C under slight shaking on an orbital shaker (catalog#980173, Talboys, Troemner, Thorofare, NJ, USA). After three washes with TBS-T, the membrane was incubated with LI-COR goat anti-Rabbit antibody IRDye 800CW (catalog#925-32211, LI-COR Bioscience, Lincoln, NE, USA) for 1.5h at RT. After three washes with TBS-T the membrane was developed using the LI-COR Odyssey CLx system (LI-COR Bioscience, Lincoln, NE, USA) using LI-COR Image Studio software (Ver.5.2) and quantification of band intensity was performed by ImageJ (NIH, Bethesda, MD, USA).

Bulk RNAseq and bioinformatic analysis of mouse hippocampal samples: Sequence reads were aligned to the mouse genome (Ensembl, GRCm38) using the STAR sequence alignment tool (version 2.7) (*82*) and gene count matrices were generated. Differential gene expression was analyzed using the DESeq2 pipeline (*83*) in R and volcano plots were generated using the open-source Enhanced Volcano package in R (https://github.com/kevinblighe/EnhancedVolcano).

Bulk RNAseq and small RNA/miRNAseq of hiPSC-derived cortical neurons at DIV8: For bulk RNAseq, Poly(A) RNA sequencing library was prepared following Illumina's TruSeq-stranded-mRNA (Illumina, San Diego, CA, USA) sample preparation protocol. RNA integrity was checked with Bioanalyzer 2100 (Agilent, CA, USA). Poly(A) tail-containing mRNAs were purified using

oligo-(dT) magnetic beads with two rounds of purification. After purification, poly(A) RNA was fragmented using divalent cation buffer in elevated temperature. Quality control analysis and quantification of the sequencing library were performed using Agilent Technologies 2100 Bioanalyzer High Sensitivity DNA Chip (Agilent, CA, USA). Paired-ended sequencing was performed on Illumina's NovaSeq 6000 (LC Sciences, Houston, TX, USA) sequencing system. For miRNAseq, total RNA quality and quantity was analyzed with Bioanalyzer 2100 (Agilent, CA, USA), with RIN number >7.0. Approximately 1 ug of total RNA was then used to prepare small RNA library according to the protocol of TruSeq Small RNA Sample Prep Kits (Illumina, San Diego, CA, USA). Then, a single-end sequencing 50bp on an Illumina Hiseq 2500 following the vendor's recommended protocol was conducted.

Bioinformatics analysis of human neuron bulk RNAseq at DIV8: Cutadapt (*84*) and in house perl scripts were used to remove the reads that contained adaptor contamination, low quality bases and undetermined bases. Sequence quality was subsequently verified using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). HISAT2 (*85*) was used to map reads to the genome of ftp://ftp.ensembl.org/pub/release-101/fasta/homo_sapiens/dna/. The mapped reads of each sample were assembled using StringTie (*86*). Then, all transcriptomes were merged to reconstruct a comprehensive transcriptome using perl scripts and GffCompare. After the final transcriptome was generated, StringTie and edgeR (*87*) were used to estimate the expression levels of all transcripts. StringTie was used to assess expression levels for mRNAs by calculating FPKM. The differentially expressed mRNAs were selected with log2 (fold change) >1 or log2 (fold change) <-1 and with statistical significance (p value < 0.05) by R package edgeR. For the VolcanoPlot visualization, the web-based R package Shiny application "VolcanoPlot" (https://paolo.shinyapps.io/ShinyVolcanoPlot/) was used. DEGs (adj. Pvalue<0.05) were plotted by selecting the axes ((Log2(FC) range= -2.5/2.5 and -Log10(Pvalue)=15) and setting the cutoff selection (P-value threshold=1.3 (0.05), Log2(FC) threshold 0.4 and 3). The GO-Term enrichment

analysis was performed for the up- and downregulated protein-coding genes (1937/2094, DEG) by using the standard setting (g:SCS threshold) of the gProfiler webtool (https://biit.cs.ut.ee/gprofiler/gost) (*88*). TargetScan (v8.0, http://www.targetscan.org/vert_80/) was used for miRNA binding site prediction (*89*). Intersection of genes and predicted targets were conducted by using the VIB / UGent Bioinformatics & Evolutionary Genomics (Gent, Belgium) webtool "Venn" (https://bioinformatics.psb.ugent.be/webtools/Venn/).

Bioinformatics analysis of human neuron miRNA-seq at DIV8: Raw reads were subjected to an in-house program, ACGT101-miR (LC Sciences, Houston, TX, USA) to remove adapter dimers, junk, low complexity, common RNA families (rRNA, tRNA, snRNA, snoRNA) and repeats. Subsequently, unique sequences with length in 18~26 nucleotide were mapped to specific species precursors in miRBase (v22.0) by BLAST search to identify known miRNAs and novel 3p- and 5p- derived miRNAs. Length variation at both 3' and 5' ends and one mismatch inside of the sequence were allowed in the alignment. The unique sequences mapping to specific species mature miRNAs in hairpin arms were identified as known miRNAs. The unique sequences mapping to the other arm of known specific species precursor hairpin opposite to the annotated mature miRNA-containing arm were considered to be novel 5p- or 3p derived miRNA candidates. The remaining sequences were mapped to other selected species precursors (with the exclusion of specific species) in miRBase 22.0 by BLAST search, and the mapped pre-miRNAs were further BLASTed against the specific species genomes to determine their genomic locations. The above two mentioned mapped 5p and 3p sequences were defined as known miRNAs. The unmapped sequences were BLASTed against the specific genomes, and the hairpin RNA structures containing sequences were predicted from the flank 80 nt sequences using RNAfold (http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi) software. The criteria for secondary structure prediction were: (1.) number of nucleotides in one bulge in stem (≤12) (2.) number of base pairs in the stem region of the predicted hairpin (≥16) (3.) cutoff of free energy (kCal/mol ≤-

15) (4.) length of hairpin (up and down stems + terminal loop ≥50) (5.) length of hairpin loop (≤20). (6.) number of nucleotides in one bulge in mature region (≤8) (7.) number of biased errors in one bulge in mature region (≤4) (8.) number of biased bulges in mature region (≤2) (9.) number of errors in mature region (≤7) (10.) number of base pairs in the mature region of the predicted hairpin (≥12) (11.) percent of mature in stem (≥80). For the VolcanoPlot visualization, the web-based R package Shiny application "VolcanoPlot" (https://paolo.shinyapps.io/ShinyVolcanoPlot/) was used. DEmiRs (Pvalue<0.05) of known miRNAs were plotted by selecting the axes ((Log2(FC) range= -5/5 and -Log10(Pvalue)=10) and setting the cutoff selection (P-value threshold=1.3 (0.05), Log2(FC) threshold 0.4). For the GO-term enrichment analysis of the up- and down-regulated miRNAs (153/133, DEmiRs) the webtool miRNet 2.0 (https://www.mirnet.ca/) with standard settings (tissue: nervous, targets: genes [miRTarBase 8.0]) was used (*30*). TargetScan (v8.0, http://www.targetscan.org/vert_80/) was used for all miRNA binding site prediction (*89*) for miR-185-5p, miR1306-5p and miR-1286 and using the biochemical predicted occupancy model (*90*) for table sorting.

Bulk RNAseq and bioinformatic analysis of NGN2-induced neurons at DIV21: We used poly-A pull-down to enrich mRNAs from total RNA samples, then proceed with library construction using Illumina TruSeq chemistry (Illumina, San Diego, CA, USA). Libraries were then sequenced using Illumina NovaSeq 6000 at Columbia Genome Center. We multiplexed samples in each lane, which yields targeted number of paired-end 100bp reads for each sample. We used RTA (Illumina) for base calling and bcl2fastq2 (version 2.19) for converting BCL to fastq format, coupled with adaptor trimming. We performed a pseudoalignment to a kallisto index created from transcriptomes (Ensembl v96, Human:GRCh38.p12) using kallisto (0.44.0) (*91*). We tested for differentially expressed genes using DESeq2 (adj. Pvalue<0.05), R packages designed to test differential expression between two experimental groups from RNA-seq counts data. Intersection of DEGs were conducted by using the VIB / UGent Bioinformatics & Evolutionary Genomics

(Gent, Belgium) webtool "Venn" (https://bioinformatics.psb.ugent.be/webtools/Venn/). GO-Term enrichment analysis was performed for the up- and downregulated DEGs Q5(Ctrl)/Q6(22q11.2) and normalized up- and downregulated DEGs in Q6/EMC10^{HET} and Q6/EMC10^{HOM} by using the standard setting (g:SCS threshold) of the gProfiler webtool https://biit.cs.ut.ee/gprofiler/gost) (*88*). Heatmaps of DEGs that were normalized in Q6/EMC10^{HET} and Q6/EMC10^{HOM} were generated with the R based web tool Heatmapper (http://www.heatmapper.ca) (*92*). PPI network analysis of the rescued 103 DEGs in Q6/EMC10^{HET} and Q6/EMC10^{HOM} conditions were performed by using the web-application konnect2prot (*93*). Hereby, GO-Term enrichment analysis of the identified 30 matched DEGs were performed by using g-Profiler webtool as indicated above.

Behavioral assays:

Open Field assay: The open field activity assay was performed as described earlier (*19*). In brief, mouse activity was monitored in a clear illuminated acrylic chamber (25 cm x 25 cm) equipped with infrared sensors to automatically record horizontal and vertical activity (Coulbourn Instruments, Whitehall, PA, USA). Each mouse was initially placed in the center of the chamber and its activity was recorded and collected in 1-min bins for 1 h using TruScan (v1.012-00) software (Coulbourn Instruments, Whitehall, PA, USA). The floors and walls of the open field were cleaned with 70% ethanol between trials.

Social Memory assay: Assays were performed as described earlier in juvenile (postnatal day 22-24) (*26*) and adult (*6, 19*) mice. All experimental mice were single housed, transferred to the testing room one hour prior to testing and returned to their home cages after the completion of the experiment. Both male and female were tested in the juvenile SM assays, in the TAM/corn oil treatment assays as well as in the ASO1 assays. Only males were tested in the ASO2 assays. For the adult SM assays, stimulus mice (C57 BL/6J) were obtained from Jackson Laboratory (Bar Harbor, ME, USA). All stimulus mice were between the ages of 3-4 weeks. Test and stimulus mice were sex matched in the experimental trials. All trials were recorded using a video camera

(Webcam Pro 9000, Logitech, Lausanne, Switzerland) and recorder software (Logitech video recording software). Stimulus mice were color marked on the tails to distinguish the stimulus mice from the test mice, during video analysis. The videos were manually scored for total interaction time over the course of the trials for interactions initiated by the test animal including anal sniffing, nose-to-nose touch and close following. For the novel/familiar paradigm, test and stimulus (novel) mice were placed together in a neutral cage and the interaction was recorded (trial 1). One hour after trial 1, the same stimulus (familiar) mouse was placed together with the test mouse and the interaction was recorded again (trial 2). A similar procedure was followed for the control novel/novel paradigm, except that we used different stimulus mice for trial 1 and trial 2 such that at trial 2 the stimulus mice were also novel for the experimental mice. Trials with experimental mice showing highly aggressive behavior towards the stimulus mice or mice that interacted for less than 24s in trial 1 were excluded from the analysis.

Contextual Fear Conditioning assay: Contextual Fear Conditioning assays were performed as described earlier (*5, 19*) using a Coulbourn animal shocker (Model H13-15 110V, Coulbourn Instruments, Whitehall, PA, USA). Sound levels were checked with a Digital Sound Level Meter (Model: 407730, Extech Instruments, MA, USA) before beginning the trials. Using a cotton swab, pure lemon extract (McCormick & Co, Hunt Valley, MD, USA) was introduced into the testing chamber adding 9 different but equal distributed spots on a napkin. Test mice were placed in the test chamber and received 2 pairs of a tone (30s, 82db) and a co-terminating shock (2s, 0.7mA). Mice were then carefully picked with forceps and returned to their home cage. After 24 hours, mice were placed in the FC box again with same environment and lemon scent for 6 minutes in the absence of tone and shock to test for contextual memory. The box and grid were cleaned with 70% EtOH before and between every test run on both days. Videos were recorded and analyzed by using FreezeFrame 3 software (Harvard Apparatus, Holliston, MA, USA).

Y-Maze assay: The Y-maze apparatus was made from white acrylic that consists of three equal-sized arms (38 cm long, 13 cm high, and 8 cm wide) of which each arm of the Y-maze was

positioned at an equal angle and was purchased from SD Instruments (cat#7001-0419, San Diego, CA, USA). The Y-maze assay was performed as described previously in more detail (*55, 94*). In brief, adult male mice were tested on delayed alternations. Exploration in all three arms of the Y-maze was performed after a 1 h delay from an initial training phase of 10 min, where one arm of the maze was blocked (delayed alternation). Delayed alternation (%) was calculated as the number of entries in all three arms divided by the total number of entries in the first 5 min of the 10 min test phase whereas the number of entries per arm was used as a measurement of activity and locomotion. The movement of mice was recorded with a camera mounted above the apparatus and the number of arm entries was counted manually.


A
Human 22q11.2 locus
1.5-Mb deletion
3.0-Mb deletion
B
TBR1
TUJ1
DAPI
Merge
Q5(Ctrl)
Q6 (22q11.2)
100μm
C
miR-1306-3p
miR-185-3p
miR-185-5p
miR-1306-5p
miR-1286
−log10(P Value)
Q6 (22q11.2)/Q5 (Ctrl) log2 (Fold-change)
D
E
F
Q5 (Ctrl)
Q6 (22q11.2)
Rel. EMC10 mRNA expression
day 8
day 20
day 34
G
Q5 (Ctrl)
Q6 (22q11.2)
25 kDa
50 kDa
EMC10
TUBULIN
H
Day 21
GFP
DAPI
MAP2
I
J
K
Q2 (Ctrl)
Q1 (22q11.2)
Q20 (Ctrl)
Q27 (22q11.2)
day 21

Fig.1


A
Q5 (Ctrl)
Q6 (22q11.2)
Rel. RNA Amount
1.50
1.25
1.00
0.75
0.50
0.25
0.00
**
miR-185
B
Rel. RNA Amount
p=0.062
miR-485
C
Rel. EMC10 mRNA expression
*
*
Ctrl mimic
miR-185
miR-485
D
Rel. EMC10 mRNA expression
**
*
*
CTR mimic
miR-185
miR-485
miR-185+miR-485
E
Rel. EMC10 mRNA expression
2.5
2.0
1.5
1.0
0.5
0.0
*
**
Ctrl inhibitor
miR-185
miR-485

Fig.2


A
Day 21
GFP
DAPI
MAP2
Q6/EMC10HET
Q6/EMC10HOM
B
Rel. EMC10 mRNA expression
Q5
Q6
Q6/EMC10HET
Q6/EMC10HOM
C
Q5
Q6
Q6/EMC10HET
Q6/EMC10HOM
D
Total neuronal length (µm)/cell
E
Number of branch points/cell
F
Total number of dendrites/cell
G
Number of primary dendrites/cell
H
KCl
Fluorescence intensity ratio (F/F0)
Time (s)
I
Fluorescence intensity (norm.)
J
111 genes
126 genes
BP terms of normalized genes
nervous system development
tissue development
anatomical structure development
neuron apoptotic process
regulation of neuron apoptotic process
multicellular organism development
multicellular organismal process
embryo development
system development
anatomical structure morphogenesis
Enrichment score [-log10(adj. p-value)]
K
193 genes
189 genes
BP terms of normalized genes
nervous system development
multicellular organismal process
multicellular organism development
neuron differentiation
system development
neurogenesis
generation of neurons
cellular response to endogenous stimulus
cellular response to stimulus
developmental process
Enrichment score [-log10(adj. p-value)]

Fig.3


A
Emc10 ASO1
B
ASO
ASO1
NeuN
Hoechst
Merge
500 µm
ASO
ASO1
GFAP
Hoechst
Merge
50 µm
10 µm
Saline
ASO1
NeuN
Hoechst
Merge
C
CtrlASO-treated WT
CtrlASO-treated Df(16)A+/-
Emc10ASO-treated Df(16)A+/-
Rel. mRNA expression
HPC
PFC
0.7642
D
22q11.2 Genes
Genelist
ncRNA
Emc10
Log2 fold change
E
Interaction Time (sec)
Trial 1
Trial 2
F
Difference Score
CtrlASO-treated WT
CtrlASO-treated Df(16)A+/-
Emc10ASO-treated WT
Emc10ASO-treated Df(16)A+/-
ns

Fig.4


A
Emc10 ASO2
B
Rel. mRNA expression
C
Rel. mRNA expression
D
CtrlASO-treated WT
CtrlASO-treated Df(16)A+/-
Emc10ASO-treated Df(16)A+/-
Rel. mRNA expression
E
Interaction Time (sec)
Trial 1
Trial 2
F
Difference Score
ns
G
WT
Df(16)A+/-
% delayed spontaneous alternations
H
% delayed spontaneous alternations
ns
I
CtrlASO-treated WT
CtrlASO-treated Df(16)A+/-
Emc10ASO-treated WT
Emc10ASO-treated Df(16)A+/-
Day 1
Day 2
% Freezing
ns

Fig.5


A
Emc10ASO2
adult mouse
SM assay
Y-maze assay
SM assay
Y-maze assay
qRT-PCR assay
week after injection
3
4
8
9
10
B
SM assay
3 weeks
8 weeks
Difference Score
C
Y-maze assay
4 weeks
9 weeks
% delayed spontaneous alternations
D
qRT-PCR assay
HPC
Rel. Emc10 mRNA expression
10 weeks
E
PFC
Rel. Emc10 mRNA expression
10 weeks
F
SSC
Rel. Emc10 mRNA expression
10 weeks
CtrlASO-treated WT
CtrlASO-treated Df(16)A+/-
Emc10ASO-treated WT
Emc10ASO-treated Df(16)A+/-

Fig.6


A
Q5 (Ctrl)
Q6 (22q11.2)
B
Q5
C
Q6
D
Q5 (Ctrl)
Q6 (22q11.2)
OCT4
NANOG
OCT4
NANOG
1kb DNA ladder
bp
2000
1500
1000
500
250
E
TBR1
TUJ1
DAPI
Merge
Q5 (Ctrl)
100μm
F
OCT4
Rel. mRNA expression
day 0
day 20
G
TBR1
Rel. mRNAexpression
day 0
day 20

Fig.S1

A

Expression of 22q11.2 region miRNAs



B

Expression of miRNAs outside the 22q11.2 region



Fig.S2

A


BP terms of down-regulated miRNAs
viral reproductive process
interaction with host
neg. reg. of transcript. from RNA Pol. II promoter
positive regulation of cell cycle
cell division
intracellular protein transport
epidermal GF receptor sig. pathway
cell-matrix adhesion
G1/S transition of mitotic cell cycle
gland development
0 2 4 6 8 10
Enrichment score [-log10(adj. p-value)]


BP terms of up-regulated miRNAs
G1/S transition of mitotic cell cycle
viral reproductive process
S phase of mitotic cell cycle
S phase
viral infectious cycle
interaction with host
protein targeting to membrane
interphase of mitotic cell cycle
interphase
positive regulation of cell cycle
0 2 4 6 8
Enrichment score [-log10(adj. p-value)]

B


CC terms of down-regulated miRNAs
nucleoplasm part
nucleoplasm
cytosol
nuclear body
nucleolus
chromatin
cell leading edge
nuclear lumen
perinuclear region of cytoplasm
transcription factor complex
0 5 10 15
Enrichment score [-log10(adj. p-value)]


CC terms of up-regulated miRNAs
perinuclear region of cytoplasm
nucleolus
cytosol
chromatin
nucleoplasm part
nuclear chromatin
nuclear body
nuclear speck
nuclear chromosome part
transcription factor complex
0 2 4 6 8 10
Enrichment score [-log10(adj. p-value)]

Fig.S3


A
−log10(P.Value)
Q6 (22q11.2)/Q5 (Ctrl) log2 (Fold-change)
RANBP1
DGCR8
EMC10
B
Q5 (Ctrl)
Q6 (22q11.2)
Rel. mRNA expression
RPLP0
DGCR8
RANBP1
C
Q5 (Ctrl)
Q6 (22q11.2)
100 kDa
25 kDa
50 kDa
DGCR8
RANBP1
TUBULIN
D
BP terms of down-regulated genes
anatomical structure development
developmental process
nervous system development
multicellular organism development
system development
neurogenesis
generation of neurons
neuron differentiation
cell development
regulation of signaling
Enrichment score [-log10(adj. p-value)]
BP terms of up-regulated genes
plasma membrane bounded cell projection organization
cell projection organization
cilium organization
plasma membrane bounded cell projection assembly
cilium assembly
cell projection assembly
nervous system development
intraciliary transport
intraciliary transport involved in cilium assembly
determination of bilateral symmetry
Enrichment score [-log10(adj. p-value)]
E
CC terms of down-regulated genes
cell junction
anchoring junction
cell periphery
axon
cell projection
cytoskeleton
neuron projection
cell-cell junction
plasma membrane
synapse
Enrichment score [-log10(adj. p-value)]
CC terms of up-regulated genes
cilium
cell projection
plasma membrane bounded cell projection
intracellular anatomical structure
ciliary plasm
ciliary basal body
cytoplasm
axoneme
ciliary tip
intracellular membrane-bounded organelle
Enrichment score [-log10(adj. p-value)]
F
up-regulated genes
(bulk RNAseq)
1163
774
6478
predicted genes of
down-regulated miRNAs
(miRNAseq)
G
BP terms for miRNA targets among up-regulated DEG
nervous system development
system development
multicellular organism development
enzyme linked receptor protein sig. pathway
central nervous system development
head development
developmental process
anatomical structure development
mesenchymal cell differentiation
adult behavior
Enrichment score [-log10(adj. p-value)]
H
CC terms for miRNA targets among up-regulated DEG
cytoplasm
endoplasmic reticulum
intracellular anatomical structure
bounding membrane of organelle
organelle membrane
plasma membrane region
endomembrane system
cell projection
plasma membrane bounded cell projection
integral component of membrane
Enrichment score [-log10(adj. p-value)]

Fig.S4

A



*conserved sites among mammals

Fig.S5


A
EMC10 (transcript 201)
Intron 2-3
Exon 3
C1982-EMC10-g1
C1982-EMC10-g2
Intron 3-4
Q6/EMC10HET
C1982-NGSB-G1-CLONE1_7209_62.4
C1982-NGSB-G1-CLONE1_4335_37.6
C1982-NGSB_ref
Q6/EMC10HOM
C1982-NGSB-G2-CLONE2_10075_43.1
C1982-NGSB-G2-CLONE2_13286_56.9
C1982-NGSB_ref
B
Q6/EMC10HET
Q6/EMC10HOM
C
Q5 (Ctrl)
Q6 (22q11.2)
Q6/EMC10HET
Q6/EMC10HOM
25 kDa-
50 kDa-
RANBP1
TUBULIN
D
Rel. NANOG mRNA expression
E
Rel. OCT4 mRNA expression
F
Rel. EMC10 mRNA expression
Q5
Q6
Q6/EMC10HET
Q6/EMC10HOM
G
Q6 (22q11.2)
Q6/EMC10HET
Q6/EMC10HOM
25 kDa-
50 kDa-
EMC10
TUBULIN
H
Q6 (22q11.2)
Q6/EMC10HET
Q6/EMC10HOM
Rel. mRNA expression
GFAP
NEUROD1
VGLUT1
DLX1
BRN2

Fig.S6

A


KCl
Q5
Q6
Fluorescence intensity ratio (F/F0)
Time (s)
***

B


Fluorescence intensity (norm.)
****
Q5
Q6

Fig.S7

A


EYA3
RBFOX1
MECP2
H2AX
SPART
PRKG1
PRKG2
DIABLO
HSPB1
U2AF1
IER3
CDH2
CDH15
GRIA2
CAPN3
WWP1
COX5B
CYCS
ADARB1
FASLG
MLXIPL
ITCH
ABL1
CDON
RPS6KB1
PRKAR1B
FBLN1
HPX
BNIP2
EIF2AK2
AKT3
FN1
GLI1
PPP2R5C
MYC
HBB
SPAG9
MAPK14
PHF6
TP53
TGFB1
ITGA1
CASP1
RCSD1
MAPKAPK2
FAS
MAPK1
MAPK3
SHH
MAPKAPK3
ACTA1
PCDHGB6
PCDHGC5
UBTF
COL1A1
TNF
CAST
PCDHGB4
HSPB6
CDC25C
AKT1
AKT2
LAMA1
PRKACB
PCDHGC3
PCDHA2
PCDHGB2
CREB5
STAT3
FGF2
NOS1
SNAI2
SPHKAP
SPHK1
AR
PRKACA
PCDHGB1
NFKBIA
CASP3
PXN
PCDHGA4
PTCH2
GLI3
NFKB1
DAXX
TLN1
PCDHGA12
IHH
CHEK1
CAPN2
YY1
GNAZ
PCDHGC4
PCDHGB5
PCDHGA3
EZR
MLC1
PTK2
GNAO1
PCDHGA7
ITGB1
GNAL
PCDHGB3
PCDHGA8
PCDHGA5
LGALS3BP
E2F1
CAPN1
GNAS
PCDHGB7
PCDHGA2
PRKCD
IRAK1
GCH1
GNA13
GNAI1
LPAR2
PCDHGA11
ZIC1
SNCA
GNAI3
LIPH
PCDHGA9
PCDHGA10
IRX1
RALGPS1
FDPS
IKBKB
PTAFR
PCDHGA6
PCDHGA1
FANCE
PNRC2
GNA14
SCAP
IRAK1BP1
SERBP1
INSIG1
IFI6
GNA12
SEMA7A
PLXNC1
GNAQ
USP9X
SMN1
RGS4
FUS
MIB1
ATOH1
PROX1

B


Enriched processes of interactome
nervous system development
negative regulation of apoptotic process
regulation of apoptotoc process
positive regulation of gene expression
negative regulation of programmed cell death
protein phosphorylation
activation of protein kinase activity
phosphorylation
positive regulation of nucleic acid-templated transcription
cytokine-mediated signaling pathways
0
20
40
60
Enrichment score [-log10(p-value)]

Fig.S8


A
Interaction Time (sec)
120
80
40
Trial 1
Trial 2
***
B
WT
Df(16)A+/-
Difference Score
100
50
0
-50
-100
****

Fig.S9


A
tm1a
FRT
lacZ
loxP
FRT loxP
neo
loxP
Flp
Cre
tm1c
tm1b
lacZ
Cre
tm1d
B
Rel. Emc10-1 mRNA expression
PFC
C
Rel. Emc10 protein expression
p=0.0634
PFC
+ oil
+ TAM
- WT
- Df(16)A+/-
- Df(16)A+/-
25 kDa -
50 kDa -
Emc10
Tubulin
D
Rel. Emc10-1 mRNA expression
HPC
E
Rel. Emc10-2 mRNA expression
HPC
F
Rel. Emc10-1 mRNA expression
CB
G
Interaction Time (sec)
Trial 1
Trial 2
H
Difference Score
ns
I
Emc10tm1c+/-; UBC-cre/ERT2; WT + oil
Emc10tm1c+/-; UBC-cre/ERT2; Df(16)A+/- + oil
Emc10tm1c+/-; UBC-cre/ERT2; WT + TAM
Emc10tm1c+/-; UBC-cre/ERT2; Df(16)A+/- + TAM
Total distance traveled (cm)

Fig.S10


A
Emc10 mRNA (%UTC)
150
100
50
0
5'
3'
B
Emc10 mRNA (%UTC)
Control ASO
Emc10 ASO
Log concentrations (uM)
1
10
100
C
Left
Right
Rel. mRNA expression
Ctrl^ASO1
Emc10^ASO1
D
Left
Right
Rel. protein expression
E
GFAP
Rel. mRNA expression
ns
Uninjected
F
Aif1
Rel. mRNA expression
ns

Fig.S11


A
Interaction Time (sec)
120
80
40
0
ns
Trial 1
Trial 2
B
Ctrl^{ASO}-treated WT
Ctrl^{ASO}-treated Df(16)A$^{+/-}$
Emc10^{ASO}-treated WT
Emc10^{ASO}-treated Df(16)A$^{+/-}$
Difference Score
40
20
0
-20
-40
-60
ns
ns

Fig.S12


A
B
C
Emc10 Cortex
Emc10 TSC
Emc10 Cortex
Gene Expression (%Vehicle)
Vehicle
1466182
1466167
1466171
2 weeks
8 weeks
Time (weeks)

Fig.S13


A
ASO
ASO2
NeuN
Hoechst
Merge
200 µm
GFAP
50 µm
B
C
D
E
WT
Df(16)A+/-
Number of total arm entries
Rel. Emc10 mRNA expression
HPC
PFC
ns
F
G
H
SSC
4 weeks
9 weeks
CtrlASO-treated WT
CtrlASO-treated Df(16)A+/-
Emc10ASO-treated WT
Emc10ASO-treated Df(16)A+/-

Fig.S14

Supplementary Table S1: Clinical and demographic characteristics of 22q11.2DS/SCZ patients and healthy controls.

Columbia ID	Rutgers University ID	Gender	Diagnosis
QR20 (1)	MH0159020	male	none
QR27 (1)	MH0159027	male	schizoaffective disorder/22q11.2DS
Q1 (2*)	-	male	schizophrenia/22q11.2DS
Q2 (2*)	-	male	none
Q5 (2**)	-	female	none
Q6 (2**)	-	female	schizophrenia/22q11.2DS

1 hiPSC lines were obtained from the Stem Cell Repository of National Institute of Mental Health

2 hiPSC lines were generated by the Columbia Stem Cell Core Facility

*sibling pair

**sibling pair, same age

Supplementary Table S5: Predicted targets of miR-185-5p, miR-1286 and miR-1306-5p in *EMC10* 3'UTR.

EMC10	hsa-miR-185-5p	predicted occupancy	hsa-miR-1306-5p	predicted occupancy	hsa-miR-1286	predicted occupancy
conserved site	**8mer***	**0.2091**	-	-	-	-
poorly conserved site	7mer-A1**	0.2091	7mer-m8**	0.0082	7mer-A1***	0.0189
	-	-	-	-	7mer-A1***	0.0189
	-	-	-	-	7mer-A1***	0.0189

*conserved miRNA binding sites among mammals
**poorly conserved miRNA binding sites among human, chimp and rhesus
***poorly conserved miRNA binding sites among human and chimp

Supplementary Table S8: List of genes upregulated in Ctrl^{ASO1} treated- *Df16(A)+/-* mice compared to Ctrl^{ASO1} treated-WT mice but not in the Emc10^{ASO1} treated *Df16(A)+/-* compared to Emc10^{ASO1} treated-WT mice.

Gene	Chromosome	Description
Emc10	7	ER Membrane protein Complex subunit 10
Mir9-3hg	7	Mir9-3 host gene
Plxnd1	6	Plexin D1
Cd68	11	CD68 antigen
Gm28439	1	Predicted gene 28439
Mir22hg	11	Mir22 host gene (non-protein coding)
Adgre4	17	Adhesion G protein-coupled receptor E4
Tnn	1	Tenascin N

Supplementary Table S9: List of primer sequences used for qRT-PCRs.

Target	Forward Primer	Reverse Primer
U6 snRNA	CTCGCTTCGGCAGCACA	AACGCTTCACGAATTTGCGT
pre-miR-134	TGTGACTGGTTGACCAGAGGG	GGTGACTAGGTGGCCCACAG
pre-miR-137	GGTGACGGGTATTCTTGGGT	CGACTACGCGTATTCTTAAGCAAT
pre-miR-185	GCGAGGGATTGGAGAGAAAG	GAGGGAAGGACCAGAGGAAA
pre-miR-212	CACCTTGGCTCTAGACTGCTT	GCCGTGACTGGAGACTGTTA
pre-miR-377	TTGAGCAGAGGTTGCCCT	CAAACAAAAGTTGCCTTTGTGT
pre-miR-485	GAGAGGCTGGCCGTGATG	GACACTAGAAGAGAGGAGAG
NANOG	TTTGTGGGCCTGAAGAAAACT	AGGGCTGTCCTGAATAAGCAG
OCT4	ACAACAATGAGAACCTTCAGGAG	GCCGGTTACAGAACCACACT